New method for preparing alpha-lactalbumin-enriched compositions, related products and their use, e.g. in infant formulas

By selectively crystallizing BLG and separating BLG crystals from whey protein solution, the problem of ALA enrichment in existing technologies has been solved, realizing a method for efficient ALA enrichment under mild conditions, which is suitable for the production of safe food ingredients.

CN112770637BActive Publication Date: 2024-11-08ARLA FOODS AMBA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980052753.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-06-27
Filing Date
2019-06-26
Publication Date
2024-11-08
Estimated Expiration
2039-06-26

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently separate and enrich α-lactalbumin (ALA) from whey protein solutions without the use of organic solvents, while conventional methods typically require high purification and are not suitable for crystallization of all proteins.

Method used

ALA is enriched from whey protein solution by selectively crystallizing β-lactoglobulin (BLG) and removing BLG crystals. Non-aggregated BLG is crystallized in supersaturated whey protein solution using a salting-out method, and BLG crystals are separated from the mother liquor. The pH is then optionally adjusted and the solution is dried.

Benefits of technology

This technology enables efficient enrichment of ALA from whey protein solutions under mild conditions, providing edible protein compositions that are safe for use as food ingredients and suitable for the production of products such as infant formula.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112770637B_ABST
    Figure CN112770637B_ABST
Patent Text Reader

Abstract

The present invention relates to a novel method for producing an edible protein composition enriched in alpha-lactalbumin, which is based on the removal of beta-lactoglobulin (BLG) from a whey protein-containing raw material by selectively crystallizing non-aggregated BLG. The present invention also relates to a novel edible protein composition enriched in alpha-lactalbumin, the use of these compositions and food products comprising these compositions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel method for producing an edible protein composition rich in alpha-lactalbumin (ALA), which is based on the removal of beta-lactoglobulin (BLG) from a whey protein-containing feed by selectively crystallizing non-aggregated BLG. The present invention also relates to novel edible protein compositions rich in alpha-lactalbumin, the use of these compositions and food products containing these compositions. Background Art

[0002] The concept of milk protein fractionation is well known in the art and has developed over the past decades into a range of techniques for preparing compositions enriched in various milk protein species, each with specific properties and characteristics.

[0003] The isolation of alpha-lactalbumin (ALA) from milk serum or whey is the subject of numerous publications, usually involving multiple separation steps and typically filtration and / or chromatography techniques to obtain purified ALA.

[0004] US 5,008,376 describes an ALA separation technique using ultrafiltration. The heat precipitation method involves applying heat to the whey within a given pH range for a time sufficient to promote ALA flocculation. Such a heat precipitation method is described in US 5,455,331. The ion exchange method involves contacting the whey with an anion or cation exchanger to selectively retain the protein fraction. Such a method is described in US Pat. No. 5,077,067.

[0005] Muller et al. (Lait 83, pp. 439-451, 2003) describe a method for enriching ALA from acid whey by a specific ultrafiltration treatment of ALA and optionally a reversible precipitation. For example, the ALA precipitate is separated from the other whey proteins by centrifugation and re-dissolution.

[0006] Good precipitation yields were obtained at 55°C, pH 3.9 for 5 to 10 minutes. Summary of the invention

[0007] By chance, the inventors unexpectedly discovered that ALA can be enriched from a crude whey protein solution by selectively crystallizing BLG and removing the BLG crystals. This can be done without the use of organic solvents such as toluene. This discovery is contrary to common knowledge in the art, which teaches that proteins must be highly purified in order to crystallize them and that not all proteins can be crystallized.

[0008] The discovery has the potential to transform the way whey proteins are processed and fractionated in the dairy industry and opens the door to the efficient and gentle production of ALA-rich protein compositions that can be safely used as food ingredients in the production of infant formula products, for example.

[0009] Therefore, one aspect of the present invention relates to a method for preparing an edible whey protein composition enriched with α-lactalbumin, the method comprising the following steps:

[0010] a) providing a whey protein solution, wherein the whey protein solution comprises non-aggregated β-lactoglobulin (BLG), α-lactalbumin (ALA) and optionally other whey proteins, wherein the whey protein solution is supersaturated with BLG and has a pH of 5 to 6;

[0011] b) crystallizing non-aggregated BLG in a supersaturated whey protein solution, preferably in a salting-in mode; and

[0012] c) separating the BLG crystals from the remaining mother liquor and recovering at least some of the mother liquor;

[0013] d) providing a first composition, said first composition being derived from the recovered mother liquor;

[0014] e) Optionally, adjusting the pH of the first composition to:

[0015] i) pH 2.5 to 4.9; or

[0016] ii) pH 6.1 to 8.5;

[0017] f) Drying:

[0018] - the first composition obtained from step d) or its protein concentrate; or

[0019] - The pH adjusted first composition or its protein concentrate obtained from step e).

[0020] Another aspect of the present invention relates to an edible ALA-enriched whey protein composition, for example, obtainable by one or more of the methods described herein.

[0021] Yet another aspect of the present invention relates to a method for producing a food product, the method comprising the following steps:

[0022] a) providing a whey protein solution, wherein the whey protein solution comprises non-aggregated β-lactoglobulin (BLG), α-lactalbumin (ALA) and optionally other whey proteins, wherein the whey protein solution is supersaturated with BLG and has a pH of 5 to 6;

[0023] b) crystallizing non-aggregated BLG in a supersaturated whey protein solution, preferably in a salting-in mode; and

[0024] c) separating the BLG crystals from the remaining mother liquor and recovering at least some of the mother liquor;

[0025] d) providing a first composition, said first composition being derived from the recovered mother liquor;

[0026] e) Optionally, adjusting the pH of the first composition to:

[0027] i) pH 2.5 to 4.9; or

[0028] ii) pH 6.1 to 8.5;

[0029] f) optionally, drying the first composition or its protein concentrate obtained from step d); or drying the pH-adjusted first composition or its protein concentrate obtained from step e);

[0030] g) mixing the following components with one or more ingredients and converting the obtained mixture into a food product:

[0031] g1) the first composition obtained from step d) or a protein concentrate thereof;

[0032] g2) the pH adjusted first composition or its protein concentrate obtained from step e); and / or

[0033] g3) The dried composition obtained from step f).

[0034] Another aspect of the present invention relates to a food product comprising a whey protein composition enriched with ALA, which food product is obtainable by a food product production method such as described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 Shown are two overlaid chromatograms of a sweet whey based crude whey protein solution (solid line) and the mother liquor obtained after crystallization (dashed line); the difference between the solid and dashed lines is due to the removal of BLG crystals.

[0036] Figure 2is a microscope photograph of BLG crystals recovered from Example 2;

[0037] Figure 3 Chromatogram of BLG crystals recovered from Example 2;

[0038] Figure 4 shows the chromatograms of the raw material (solid line) and the mother liquor obtained after crystallization and removal of BLG crystals (dashed line) of Example 3;

[0039] Figure 5 shows images of starting material 3 of Example 5 before (left) and after (right) crystallization;

[0040] Figure 6 is a schematic diagram of a crystallization process variant of Example 6, which uses DCF to separate BLG crystals from the mother liquor. DETAILED DESCRIPTION

[0041] definition

[0042] In the context of the present invention, the term "β-lactoglobulin" or "BLG" relates to β-lactoglobulin from a mammalian species, e.g. in native, unfolded and / or glycosylated form, including naturally occurring gene variants. The term also includes aggregated BLG, precipitated BLG and crystallized BLG. When referring to the amount of BLG, it refers to the total amount of BLG (including aggregated BLG). The total amount of BLG is determined according to Example 1.21. The term "aggregated BLG" refers to BLG that is at least partially unfolded and aggregated with other denatured BLG molecules and / or other denatured whey proteins, typically by hydrophobic interactions and / or covalent bonds.

[0043] BLG is the most predominant protein in bovine whey and cow serum, and there are several genetic variants, with the major variants in bovine milk being labeled A and B. BLG is a lipoprotein that binds a variety of hydrophobic molecules, suggesting a role in their transport. BLG has also been shown to bind iron via siderophores, possibly playing a role in combating pathogens. The homologue of BLG is missing in human breast milk.

[0044] Bovine BLG is a relatively small protein with about 162 amino acid residues and a molecular weight of about 18.3 kDa to 18.4 kDa. As measured using nuclear magnetic resonance spectroscopy, it is primarily a dimer under physiological conditions, but dissociates into monomers at a pH below about 3, retaining its native state. However, BLG also exists as a tetramer, octamer, and other multimers under various natural conditions.

[0045] In the context of the present invention, the term "non-aggregated β-lactoglobulin" or "non-aggregated BLG" also relates to β-lactoglobulin from mammalian species, e.g. in native, unfolded and / or glycosylated form, including naturally occurring gene variants. However, the term does not include aggregated BLG, precipitated BLG or crystallized BLG. The amount or concentration of non-aggregated BLG is measured according to Example 1.2.

[0046] By calculating (m 总BLG -m 非聚集BLG ) / m 总BLG *100%, to determine the percentage of non-aggregated BLG relative to total BLG. m 总BLG is the concentration or amount of BLG measured according to Example 1.21, m 非聚集BLG is the concentration or amount of non-aggregated BLG measured according to Example 1.2.

[0047] In the context of the present invention, the term "crystalline" relates to a solid material whose constituents (eg atoms, molecules or ions) are arranged in a highly ordered microstructure, forming a crystalline lattice extending in all directions.

[0048] In the context of the present invention, the term "BLG crystal" refers to a protein crystal that mainly comprises non-aggregated BLG (preferably natural BLG) arranged in a highly ordered microstructure, forming a lattice extending in all directions. For example, a BLG crystal can be monolithic or polycrystalline, and can be, for example, a complete crystal, a crystal fragment, or a combination thereof. For example, when a complete crystal is mechanically sheared during processing, a crystal fragment is formed. The crystal fragment also has a highly ordered microstructure of the crystal, but may lack a uniform surface and / or uniform edge or angle of a complete crystal. For example, see Figure 18 of PCT Application No. PCT / EP2017 / 084553 as an example of many complete BLG crystals, and Figure 13 of PCT Application No. PCT / EP2017 / 084553 as an example of BLG crystal fragments. In both cases, BLG crystals or crystal fragments can be visually identified as well-defined, compact and pseudo-ordered structures using an optical microscope. Typically, BLG crystals or crystal fragments are at least partially transparent. In addition, it is known that protein crystals are birefringent, and this optical property can be used to identify unknown particles with a crystalline structure. On the other hand, non-crystalline BLG aggregates usually appear as open or porous masses with unclear boundaries, opaqueness, and irregular sizes.

[0049] In the context of the present invention, the term "crystallization" relates to the formation of protein crystals. For example, crystallization occurs spontaneously or is initiated by the addition of seed crystals.

[0050] “Mother liquor”

[0051] In the context of the present invention, the term "mother liquor" relates to the whey protein solution remaining after BLG has been crystallized and the BLG crystals have been at least partially removed. The mother liquor may still contain some BLG crystals, but typically only small BLG crystals that escaped separation.

[0052] In the context of the present invention, the term "edible composition" relates to a composition that is safe for human consumption and use as a food ingredient and does not contain problematic toxic components such as toluene or other hazardous organic solvents.

[0053] In the context of the present invention, the term "ALA" or "α-lactalbumin" relates to α-lactalbumin from mammalian species, e.g. in native and / or glycosylated form, including naturally occurring gene variants. The term also includes aggregated ALA and precipitated BLG. When referring to the amount of ALA, it refers to the total amount of ALA (including e.g. aggregated ALA). The total amount of ALA is determined according to Example 1.21. The term "aggregated ALA" relates to ALA that is typically at least partially unfolded and aggregated with other denatured ALA molecules and / or other denatured whey proteins, typically by hydrophobic interactions and / or covalent bonds.

[0054] Alpha-lactalbumin (ALA) is a protein present in the milk of almost all mammalian species. ALA forms the regulatory subunit of the lactose synthase (LS) heterodimer, while β-1,4-galactosyltransferase (β4Gal-T1) forms the catalytic component. Together, these proteins allow LS to produce lactose by transferring the galactose moiety to glucose. One of the main structural differences of β-lactoglobulin is that ALA does not have any free thiol groups that could serve as a starting point for covalent aggregation reactions.

[0055] In the context of the present invention, the term "non-aggregated ALA" also relates to ALA from mammalian species, e.g. in native, unfolded and / or glycosylated form, including naturally occurring gene variants. However, the term does not include aggregated ALA or precipitated ALA. The amount or concentration of non-aggregated BLG is determined according to Example 1.2.

[0056] By calculating (m 总ALA -m 非聚集ALA ) / m 总ALA *100%, to determine the percentage of non-aggregated ALA relative to total ALA. m 总ALA is the concentration or amount of ALA measured according to Example 1.21, m 非聚集ALA is the concentration or amount of non-aggregated ALA measured according to Example 1.2.

[0057] In the context of the present invention, an "ALA-enriched" or "ALA-rich" composition has a higher weight percentage of ALA relative to the total amount of protein than the starting material from which the composition is derived.

[0058] In the context of the present invention, the term "caseinomacropeptide" or "CMP" relates to a hydrophilic peptide, residues 106-169, derived from "κ-CN" or "κ-casein" of mammalian species by hydrolysis of aspartic proteases such as chymosin, e.g. in native and / or glycosylated form, including naturally occurring genetic variants.

[0059] The term "whey" relates to the liquid phase remaining after casein in milk has been precipitated and removed. For example, casein is precipitated by acidifying milk and / or using rennet. There are several types of whey, such as "sweet whey", which is a whey product produced upon precipitation of casein by rennet, and "acid whey", which is a whey product produced upon precipitation of casein by acid. For example, casein is precipitated by acid by adding edible acids or by bacterial cultures.

[0060] The term "serum" relates to the liquid that remains when casein and milk fat globules are removed from milk, for example by microfiltration or macroporous ultrafiltration. Serum may also be referred to as "ideal whey".

[0061] The term "whey proteins" or "serum proteins" relates to proteins present in whey.

[0062] In the context of the present invention, the term "whey protein" relates to proteins found in whey or milk hemp. The whey protein may be a subset of the protein species found in whey or milk hemp, even a single whey protein species, or it may be the complete set of protein species found in whey or / and milk hemp.

[0063] The term "casein" relates to casein found in milk, including the two natural micellar caseins found in raw milk, individual casein species and caseinates.

[0064] In the context of the present invention, a "supersaturated" or "BLG supersaturated" liquid contains a concentration of dissolved non-aggregated BLG that is higher than the saturation point of non-aggregated BLG in the liquid under given physical and chemical conditions. The term "supersaturation" is well known in the art of crystallization (see, for example, Gérard Coquerela, Crystallization of molecular systems from solution: phase diagrams, supersaturation and other basic concepts, Chemical Society Reviews 2014, pp. 2286-2300, No. 7), and supersaturation can be determined by a variety of different measurement techniques (e.g., by spectroscopy or particle size analysis). In the context of the present invention, the supersaturation of BLG is determined by the following procedure.

[0065] Procedure for detecting whether a liquid is supersaturated with BLG under specific conditions:

[0066] a) Transfer 50 mL of the liquid sample to be tested into a centrifuge tube (VWR catalog number 525-0402) with a height of 115 mm, an inner diameter of 25 mm, and a capacity of 50 mL. During steps a) to h), care should be taken to maintain the sample and its subsequent fractions in the original physical and chemical conditions of the liquid;

[0067] b) immediately centrifuging the sample at 3000 g for 3.0 minutes with an acceleration of up to 30 seconds and a deceleration of up to 30 seconds;

[0068] c) After centrifugation, immediately transfer as much supernatant as possible to a second centrifuge tube (of the same type as in step a) (if a precipitate has formed, do not disturb the precipitate);

[0069] d) taking a subsample of 0.05 mL of the supernatant (subsample A);

[0070] e) adding 10 mg of BLG crystals having a particle size of at most 200 μm (non-aggregated BLG having a purity of at least 98% relative to the total solids) to a second centrifuge tube and stirring the mixture;

[0071] f) allowing the second centrifuge tube to stand at the original temperature for 60 minutes;

[0072] g) immediately after step f), centrifuge the second centrifuge tube at 500 g for 10 minutes and take another 0.05 mL subsample of the supernatant (subsample B);

[0073] h) recovering the centrifugal precipitate (if any) from step g), resuspending it in MilliQ water, and immediately checking the suspension for the presence of crystals observable under a microscope;

[0074] i) The concentration of non-aggregated BLG in sub-samples A and B was determined using the method outlined in Example 1.2 - the results are expressed as % w / w of BLG relative to the total weight of the sub-sample. The concentration of non-aggregated BLG in sub-sample A is referred to as C BLG,A , the concentration of non-aggregated BLG in subsample B is called C BLG,B ;

[0075] j) If C BLG,B Below C BLG,A and crystals are observed in step i), then the liquid from which the sample of step a) was taken is (under the specific conditions) supersaturated.

[0076] In the context of the present invention, the terms "liquid" and "solution" include compositions that do not contain particulate matter, as well as compositions that contain a liquid in combination with solid and / or semi-solid particles (e.g., protein crystals or other protein particles). Thus, a "liquid" or "solution" may be a suspension or even a slurry. However, "liquids" and "solutions" are preferably pumpable.

[0077] In the context of the present invention, the terms "whey protein concentrate" (WPC) and "serum protein concentrate" (SPC) relate to dry or aqueous compositions comprising a total amount of 20-89% w / w protein relative to the total amount of solids.

[0078] Preferably, the WPC or SPC comprises:

[0079] 20-89% w / w protein relative to total solids;

[0080] 15-70% w / w non-aggregated BLG relative to the total amount of protein;

[0081] 8-50% w / w ALA relative to the total amount of protein; and

[0082] 0-40% w / w CMP relative to protein.

[0083] Alternatively, but also preferably, the WPC or SPC may comprise:

[0084] 20-89% w / w protein relative to total solids;

[0085] 15-90% w / w non-aggregated BLG relative to the total amount of protein;

[0086] 4-50% w / w ALA relative to the total amount of protein; and

[0087] 0-40% w / w CMP relative to protein.

[0088] Preferably, the WPC or SPC comprises:

[0089] 20-89% w / w protein relative to total solids;

[0090] 15-80% w / w non-aggregated BLG relative to the total amount of protein;

[0091] 4-50% w / w ALA relative to the total amount of protein; and

[0092] 0-40% w / w CMP relative to protein.

[0093] More preferably, the WPC or SPC comprises:

[0094] 70-89% w / w protein relative to total solids;

[0095] 30-90% w / w non-aggregated BLG relative to the total amount of protein;

[0096] 4-35% w / w ALA relative to the total amount of protein; and

[0097] 0-25% w / w CMP relative to protein.

[0098] Typically, SPC contains no CMP or only trace amounts of CMP.

[0099] The terms "whey protein isolate" (WPI) and "serum protein isolate" (SPI) relate to dry or aqueous compositions comprising a total amount of protein of 90-100% w / w relative to the total amount of solids.

[0100] Preferably, the WPI or SPI comprises:

[0101] 90-100% w / w protein relative to total solids;

[0102] 15-70% w / w non-aggregated BLG relative to the total amount of protein;

[0103] 8-50% w / w ALA relative to the total amount of protein; and

[0104] 0-40% w / w CMP relative to the total amount of protein.

[0105] Alternatively, but preferably, the WPI or SPI may comprise:

[0106] 90-100% w / w protein relative to total solids;

[0107] 30-95% w / w non-aggregated BLG relative to the total protein;

[0108] 4-35% w / w ALA relative to the total amount of protein; and

[0109] 0-25% w / w CMP relative to the total amount of protein.

[0110] Preferably, the WPI or SPI comprises:

[0111] 90-100% w / w protein relative to total solids;

[0112] 30-90% w / w non-aggregated BLG relative to the total amount of protein;

[0113] 4-35% w / w ALA relative to the total amount of protein; and

[0114] 0-25% w / w CMP relative to the total amount of protein.

[0115] Typically, SPI contains no CMP or only trace amounts of CMP.

[0116] The terms “consisting essentially of” and “consisting essentially of” mean that the claim or feature covers the specified materials or steps as well as those that do not materially affect the basic and novel characteristics of the claimed invention.

[0117] In the context of the present invention, the phrase "Y and / or X" means "Y" or "X" or "Y and X". Following the same logic, the phrase "n1, n2, ..., n i-1 and / or i " means "n1" or "n2" or ... or "n i-1 " or "n i " or components n1, n2, ..., n i-1 and n i Any combination of .

[0118] In the context of the present invention, the term "dry" means that the composition or product comprises at most 10% w / w, preferably at most 6% w / w, more preferably even less water.

[0119] In the context of the present invention, the term "physical microbial reduction" relates to a physical interaction with a composition resulting in a reduction in the total amount of viable microorganisms of the composition. The term does not include the addition of chemicals that kill microorganisms. Furthermore, the term does not include thermal exposure of the atomized droplets of the liquid during spray drying, but includes possible preheating prior to spray drying.

[0120] In the context of the present invention, the pH of the powder refers to the pH of 10 g of powder mixed into 90 g of demineralised water, measured according to Example 1.8.

[0121] In the context of the present invention, the weight percent (% w / w) of a component of a composition, product or material refers to the weight percent of that component relative to the particular composition, product or material, unless another reference (e.g., total solids or total protein) is specifically mentioned.

[0122] In the context of the present invention, the term "weight ratio" between component X and component Y refers to the weight ratio calculated by m X / m Y The value obtained, where m X is the amount (weight) of component X, m Y is the amount of component Y (by weight).

[0123] In the context of the present invention, the term "at least pasteurized" relates to a heat treatment having a microbial killing effect equal to or higher than a heat treatment at 70°C for 10 seconds. The reference for determining the bacterial killing effect is Escherichia coli O157:H7.

[0124] In the context of the present invention, the term "whey protein solution" is used to describe a specific aqueous whey protein composition which is supersaturated with BLG in a salted-in mode and which can be used to prepare BLG crystals.

[0125] In the context of the present invention, the term "whey protein raw material" relates to a source of a whey protein solution. Typically, the whey protein raw material is WPC, WPI, SPC or SPI.

[0126] In the context of the present invention, the term "sterile" means that the sterile composition or product does not contain any living microorganisms and therefore there is no growth of microorganisms during storage at room temperature. A sterilized composition is sterile.

[0127] When a liquid, such as a beverage formulation, is sterilized and aseptically packaged in a sterile container, the liquid typically has a shelf life of at least six months at room temperature. The sterilization process kills spores and microorganisms that may cause the liquid to spoil.

[0128] In the context of the present invention the term "protein fraction" relates to the protein of the composition, eg the protein in a powder or beverage formulation.

[0129] In the context of the present invention, unless otherwise specified, the term "mineral" as used herein refers to any of major minerals, trace or trace minerals, other minerals and combinations thereof. Major minerals include: calcium, phosphorus, potassium, sulfur, sodium, chlorine, magnesium. Trace or trace minerals include: iron, cobalt, copper, zinc, molybdenum, iodine, selenium, manganese. Other minerals include: chromium, fluorine, boron, lithium and strontium.

[0130] In the context of the present invention, unless otherwise specified, the terms "lipid", "fat" and "oil" used herein are used interchangeably to refer to lipid materials derived from plants or animals or obtained by processing plants or animals. These terms also include synthetic lipid materials, as long as such synthetic materials are suitable for human consumption.

[0131] In the context of the present invention, the term "transparent" encompasses beverage formulations that have a visually clear appearance and allow light to pass through and appear different images therethrough. A clear beverage has a turbidity of at most 200 NTU.

[0132] In the context of the present invention, the term "opaque" encompasses beverage formulations having a visually unclear appearance and a turbidity greater than 200 NTU.

[0133] In the context of the present invention, a "protein concentrate" of a first solution or a "protein concentrate thereof" relates to a second solution having, compared to the first solution: i) a higher weight percentage of total protein based on total solids; and / or ii) a higher weight percentage of total protein based on total weight. For example, the protein concentrate may be obtained by removing only water and / or removing non-protein solids (e.g. carbohydrates and salts) from the first solution. Preferably, the protein concentrate has substantially the same pH as the first solution; i.e., the pH of the protein concentrate is preferably at most 0.3 higher or lower than the pH of the first solution, more preferably at most 0.2 higher or lower than the pH of the first solution, even more preferably at most 0.1 higher or lower than the pH of the first solution.

[0134] In the context of the present invention, the term "other proteins" refers to proteins other than BLG or ALA. Typically, the other proteins present in the whey protein solution comprise milk serum or one or more non-BLG / ALA proteins found in whey. Non-limiting examples of such proteins are: bovine serum albumin, immunoglobulins, casein macropeptide (CMP), osteopontin, lactoferrin and milk fat globule membrane protein.

[0135] Therefore, preferably, the whey protein solution may comprise at least one other whey protein selected from the group consisting of bovine serum albumin, immunoglobulins, casein macropeptide (CMP), osteopontin, lactoferrin, milk fat globule membrane protein and combinations thereof.

[0136] In the context of the present invention, the term "mother liquor" relates to the whey protein solution remaining after non-aggregated BLG has crystallized and the BLG crystals have been at least partially removed. The mother liquor may still contain some BLG crystals, but typically only small BLG crystals that escaped separation.

[0137] As mentioned above, one aspect of the present invention relates to a method for preparing an edible whey protein composition enriched with α-lactalbumin, the method comprising the following steps:

[0138] a) providing a whey protein solution, the whey protein solution comprising non-aggregated BLG, ALA and optionally other whey proteins, the whey protein solution being supersaturated with BLG and having a pH of 5 to 6;

[0139] b) crystallizing non-aggregated BLG in a supersaturated whey protein solution, preferably in a salting-in mode; and

[0140] c) separating the BLG crystals from the remaining mother liquor and recovering at least some of the mother liquor;

[0141] d) providing a first composition, said first composition being derived from the recovered mother liquor and optionally the spent wash liquor;

[0142] e) Optionally, adjusting the pH of the first composition to:

[0143] i) pH 2.5 to 4.9; or

[0144] ii) pH 6.1 to 8.5;

[0145] f) Drying:

[0146] - the first composition obtained from step d) or its protein concentrate; or

[0147] - The pH adjusted first composition or its protein concentrate obtained from step e).

[0148] In some preferred embodiments of the present invention, the method further comprises physical reduction of microorganisms, preferably after pH adjustment in step e) and before drying in step f).

[0149] As mentioned above, step a) of the present invention involves providing a whey protein solution comprising non-aggregated BLG, ALA and at least one other whey protein.

[0150] In some embodiments of the invention, the whey protein solution comprises at most 10% w / w, preferably at most 5% w / w, more preferably at most 1% w / w, even preferably at most 0.5% w / w casein relative to the total amount of protein. In some preferred embodiments of the invention, the whey protein solution does not comprise any detectable amount of casein.

[0151] In some preferred embodiments of the present invention, the whey protein solution of step a) comprises at least 5% w / w of other whey proteins relative to the total amount of protein. Preferably, the whey protein solution of step a) comprises at least 10% w / w of other whey proteins relative to the total amount of protein. More preferably, the whey protein solution of step a) comprises at least 15% w / w of other whey proteins relative to the total amount of protein. Even more preferably, the whey protein solution of step a) comprises at least 20% w / w of other whey proteins relative to the total amount of protein. Most preferably, the whey protein solution of step a) may comprise at least 30% w / w of other whey proteins relative to the total amount of protein.

[0152] In other preferred embodiments of the present invention, the whey protein solution of step a) comprises at least 1% w / w of other whey proteins relative to the total amount of protein. Preferably, the whey protein solution of step a) comprises at least 2% w / w of other whey proteins relative to the total amount of protein. Even more preferably, the whey protein solution of step a) comprises at least 3% w / w of other whey proteins relative to the total amount of protein. Most preferably, the whey protein solution of step a) may comprise at least 4% w / w of other whey proteins relative to the total amount of protein.

[0153] In other preferred embodiments of the present invention, the whey protein solution of step a) comprises at least 35% w / w of other whey proteins relative to the total amount of protein. Preferably, the whey protein solution of step a) may comprise at least 40% w / w of other whey proteins relative to the total amount of protein. More preferably, for example, the whey protein solution of step a) may comprise at least 45% w / w of other whey proteins relative to the total amount of protein. Even more preferably, the whey protein solution of step a) may comprise at least 50% w / w of other whey proteins relative to the total amount of protein.

[0154] In some preferred embodiments of the present invention, the whey protein solution of step a) contains 5 to 90% w / w of other whey proteins relative to the total amount of protein. Preferably, the whey protein solution of step a) may contain 10 to 80% w / w of other whey proteins relative to the total amount of protein. For example, the whey protein solution of step a) may contain whey proteins containing, for example, 20 to 70% w / w of other whey proteins relative to the total amount of protein. Preferably, the whey protein solution of step a) contains 30 to 70% w / w of other whey proteins relative to the total amount of protein.

[0155] As described above, the inventors have discovered that non-aggregated BLG can be crystallized without the use of organic solvents. This purification method can also be used to refine preparations containing whey proteins that have undergone some BLG purification; this purification method provides a simple method for further improving the purity of non-aggregated BLG. Therefore, in some preferred embodiments of the present invention, the whey protein solution of step a) contains 1 to 20% w / w of other whey proteins relative to the total amount of protein. Preferably, the whey protein solution of step a) may contain 2 to 15% w / w of other whey proteins relative to the total amount of protein. Even more preferably, for example, the whey protein solution of step a) may contain 3 to 10% w / w of other whey proteins relative to the total amount of protein.

[0156] In some embodiments of the invention, the whey protein solution of step a) comprises at least 5% w / w ALA relative to the total amount of protein. Preferably, the whey protein solution of step a) comprises at least 10% w / w ALA relative to the total amount of protein. Even more preferably, the whey protein solution of step a) comprises at least 15% w / w ALA relative to the total amount of protein. Alternatively, the whey protein solution of step a) may comprise at least 20% w / w ALA relative to the total amount of protein.

[0157] In some preferred embodiments of the present invention, the whey protein solution of step a) comprises at least 25% w / w ALA relative to the total amount of protein. Preferably, the whey protein solution of step a) comprises at least 30% w / w ALA relative to the total amount of protein. The whey protein solution of step a) preferably comprises at least 35% w / w ALA relative to the total amount of protein. Even more preferably, the whey protein solution of step a) may comprise at least 40% w / w ALA relative to the total amount of protein.

[0158] In some preferred embodiments of the present invention, the whey protein solution of step a) contains 5 to 95% w / w of ALA relative to the total amount of protein. Preferably, the whey protein solution of step a) contains 5 to 70% w / w of ALA relative to the total amount of protein. Even more preferably, the whey protein solution of step a) may contain 10 to 60% w / w of ALA relative to the total amount of protein. The whey protein solution of step a) preferably contains 12 to 50% w / w of ALA relative to the total amount of protein. Even more preferably, the whey protein solution of step a) may contain 20 to 45% w / w of ALA relative to the total amount of protein.

[0159] It is generally preferred that at least some of the ALA in the compositions and products described herein comprise at least some non-aggregated ALA. Preferably, at least 25% of the ALA is non-aggregated ALA. More preferably, at least 50% of the ALA is non-aggregated ALA. Even more preferably, at least 70% of the ALA is non-aggregated ALA. Most preferably, at least 90% of the ALA is non-aggregated ALA. Even more preferably, about 100% of the ALA can be non-aggregated ALA.

[0160] In some preferred embodiments of the present invention, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) is at least 0.01. Preferably, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) is at least 0.5. Even more preferably, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) is at least 1, such as at least 2. For example, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) may be at least 3. The amount and concentration of non-aggregated BLG and other proteins in the whey protein solution and the whey protein raw material refer to dissolved proteins, excluding precipitated or crystallized proteins.

[0161] In some preferred embodiments of the present invention, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) is 0.01 to 20. Preferably, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) is 0.2 to 10. Even more preferably, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) is 0.5 to 4. For example, the weight ratio between non-aggregated BLG and ALA in the whey protein solution of step a) may be 1 to 3.

[0162] In some preferred embodiments of the present invention, the whey protein solution of step a) comprises at least 1% w / w of non-aggregated BLG relative to the total amount of protein. Preferably, the whey protein solution of step a) comprises at least 2% w / w of non-aggregated BLG relative to the total amount of protein. Even more preferably, the whey protein solution of step a) comprises at least 5% w / w of non-aggregated BLG relative to the total amount of protein. Preferably, the whey protein solution of step a) may comprise at least 10% w / w of non-aggregated BLG relative to the total amount of protein.

[0163] In some preferred embodiments of the present invention, the whey protein solution of step a) contains at least 12% w / w of non-aggregated BLG relative to the total amount of protein. For example, the whey protein solution of step a) may contain at least 15% w / w of non-aggregated BLG relative to the total amount of protein. For example, the whey protein solution of step a) may contain at least 20% w / w of non-aggregated BLG relative to the total amount of protein. Alternatively, the whey protein solution of step a) may contain at least 30% w / w of non-aggregated BLG relative to the total amount of protein.

[0164] In some particularly preferred embodiments of the present invention, the whey protein solution of step a) contains up to 95% w / w of non-aggregated BLG relative to the total amount of protein. Preferably, the whey protein solution of step a) may contain up to 90% w / w of non-aggregated BLG relative to the total amount of protein. More preferably, for example, the whey protein solution of step a) may contain up to 85% w / w of non-aggregated BLG relative to the total amount of protein. Even more preferably, for example, the whey protein solution of step a) may contain up to 80% w / w of non-aggregated BLG. Preferably, the whey protein solution of step a) may contain up to 78% w / w of non-aggregated BLG relative to the total amount of protein. Preferably, the whey protein solution of step a) may contain up to 75% w / w of non-aggregated BLG relative to the total amount of protein.

[0165] In some preferred embodiments of the present invention, the whey protein solution of step a) contains 1 to 95% w / w of non-aggregated BLG relative to the total amount of protein. Preferably, the whey protein solution of step a) may contain 5 to 90% w / w of non-aggregated BLG relative to the total amount of protein. More preferably, the whey protein solution of step a) contains 10 to 85% w / w of non-aggregated BLG relative to the total amount of protein. Even more preferably, the whey protein solution of step a) contains 10 to 80% w / w of non-aggregated BLG relative to the total amount of protein. Most preferably, the whey protein solution of step a) may contain 20 to 70% w / w of non-aggregated BLG relative to the total amount of protein.

[0166] In other preferred embodiments of the present invention, the whey protein solution of step a) contains 10-95% w / w of non-aggregated BLG relative to the total amount of protein. Preferably, the whey protein solution of step a) may contain 12-90% w / w of non-aggregated BLG relative to the total amount of protein. More preferably, the whey protein solution of step a) contains 15-85% w / w of non-aggregated BLG relative to the total amount of protein. Even more preferably, the whey protein solution of step a) contains 15-80% w / w of non-aggregated BLG relative to the total amount of protein. Most preferably, the whey protein solution of step a) may contain 30-70% w / w of non-aggregated BLG relative to the total amount of protein.

[0167] In some preferred embodiments of the present invention, the whey protein solution of step a) comprises at least 0.4% w / w non-aggregated BLG relative to the weight of the whey protein solution. Preferably, the whey protein solution comprises at least 1.0% w / w non-aggregated BLG. More preferably, the whey protein solution comprises at least 2.0% w / w non-aggregated BLG. Even more preferably, the whey protein solution comprises at least 4% w / w non-aggregated BLG.

[0168] Higher concentrations of non-aggregated BLG are even more preferred. Preferably, the whey protein solution comprises at least 6% w / w of non-aggregated BLG. More preferably, the whey protein solution comprises at least 10% w / w of non-aggregated BLG. Even more preferably, the whey protein solution comprises at least 15% w / w of non-aggregated BLG.

[0169] In some preferred embodiments of the present invention, the whey protein solution of step a) comprises 0.4-40% w / w non-aggregated BLG relative to the weight of the whey protein solution. Preferably, the whey protein solution comprises 1-35% w / w non-aggregated BLG. More preferably, the whey protein solution comprises 4-30% w / w non-aggregated BLG. Even more preferably, the whey protein solution comprises 10-25% w / w non-aggregated BLG.

[0170] Any suitable whey protein source can be used to prepare the whey protein solution.In some preferred embodiments of the present invention, the whey protein solution comprises whey protein concentrate, whey protein concentrate, whey protein isolate, whey protein isolate or a combination thereof, or even consists thereof.

[0171] Preferably, the whey protein solution is a demineralised whey protein solution.

[0172] In the present context, the term "desalted" means that the conductivity of the whey protein solution is at most 15 mS / cm, preferably at most 10 mS / cm, even more preferably at most 8 mS / cm. The UF permeate conductivity of the desalted whey protein solution is preferably at most 7 mS / cm, more preferably at most 4 mS / cm, even more preferably at most 1 mS / cm.

[0173] Particularly preferably, the whey protein solution is a desalted whey protein concentrate, a desalted whey protein isolate, a desalted whey protein concentrate or a desalted whey protein isolate.

[0174] In some particularly preferred embodiments of the present invention, the whey protein solution comprises or even consists of the following components: desalted and pH-adjusted whey protein concentrate, whey protein concentrate, whey protein isolate, whey protein isolate or a combination thereof.

[0175] For example, the whey protein solution may comprise, or even consist of, a desalted whey protein concentrate. Alternatively, the whey protein solution may comprise, or even consist of, a desalted whey protein concentrate. Alternatively, the whey protein solution may comprise, or even consist of, a desalted whey protein isolate. Alternatively, the whey protein solution may comprise, or even consist of, a desalted whey protein isolate.

[0176] Preferably, the protein of the whey protein solution is derived from the milk of mammals, preferably from the milk of ruminants (e.g., cows, sheep, goats, buffaloes, camels, llamas, mares and / or deer). Proteins derived from bovine (milk) milk are particularly preferred. Therefore, BLG and other whey proteins are preferably bovine BLG and bovine whey proteins.

[0177] Preferably, the proteins in the whey protein solution are as close to their native state as possible, preferably having undergone only mild heat treatment, if any.

[0178] In some preferred embodiments of the present invention, the degree of lactosylation of non-aggregated BLG in the whey protein solution is at most 1. Preferably, the degree of lactosylation of non-aggregated BLG in the whey protein solution is at most 0.6. More preferably, the degree of lactosylation of non-aggregated BLG in the whey protein solution is at most 0.4. Even more preferably, the degree of lactosylation of non-aggregated BLG in the whey protein solution is at most 0.2. Most preferably, the degree of lactosylation of non-aggregated BLG in the whey protein solution is at most 0.1, such as preferably at most 0.01.

[0179] The degree of lactosylation of BLG was determined according to Czerwenka et al. (J. Agric. Food Chem. 2006, 54(23): 8874-8882).

[0180] In some preferred embodiments of the invention, the whey protein solution has a furosine value of at most 80 mg / 100 g protein. Preferably, the whey protein solution has a furosine value of at most 40 mg / 100 g protein. More preferably, the whey protein solution has a furosine value of at most 20 mg / 100 g protein. Even more preferably, the whey protein solution has a furosine value of at most 10 mg / 100 g protein. Most preferably, the whey protein solution has a furosine value of at most 5 mg / 100 g protein, for example, the furosine value is preferably 0 mg / 100 g protein.

[0181] Typically, in addition to protein, a whey protein solution also comprises other ingredients. A whey protein solution may comprise other ingredients commonly found in whey or milk whey, such as minerals, carbohydrates and / or lipids. Alternatively or additionally, a whey protein solution may comprise ingredients that are non-natural to whey or milk whey. However, preferably, such non-natural ingredients should be safe for use in food product production, preferably also safe for human consumption.

[0182] The process of the present invention is particularly advantageous for separating non-aggregated BLG from a crude whey protein solution containing other solids besides non-aggregated BLG.

[0183] For example, the whey protein solution may contain carbohydrates, such as lactose, oligosaccharides and / or hydrolysates of lactose (i.e. glucose and galactose). For example, the whey protein solution may contain 0-40% w / w (e.g. 1-30% w / w or 2-20% w / w) carbohydrates.

[0184] In some preferred embodiments of the invention, the whey protein solution comprises at most 20% w / w carbohydrates, preferably at most 10% w / w carbohydrates, more preferably at most 5% w / w carbohydrates, even more preferably at most 2% w / w carbohydrates.

[0185] The whey protein solution may further comprise lipids, for example in the form of triglycerides and / or other lipid types (eg phospholipids).

[0186] In some embodiments of the invention, the whey protein solution of step a) comprises at most 15% w / w of total lipids relative to the total solids. Preferably, the whey protein solution of step a) comprises at most 10% w / w of total lipids relative to the total solids. More preferably, the whey protein solution of step a) comprises at most 6% w / w of total lipids relative to the total solids. Even more preferably, the whey protein solution of step a) comprises at most 1.0% w / w of total lipids relative to the total solids. Most preferably, the whey protein solution of step a) comprises at most 0.5% w / w of total lipids relative to the total solids.

[0187] Typically, the total amount of protein in the whey protein solution is at least 1% w / w relative to the weight of the whey protein solution. Preferably, the total amount of protein in the whey protein solution is at least 5% w / w. More preferably, the total amount of protein in the whey protein solution is at least 10% w / w. Even more preferably, the total amount of protein in the whey protein solution is at least 15% w / w.

[0188] In some preferred embodiments of the present invention, the total amount of protein in the whey protein solution is 1-50% w / w. Preferably, the total amount of protein in the whey protein solution is 5-40% w / w. More preferably, the total amount of protein in the whey protein solution is 10-30% w / w. Even more preferably, the total amount of protein in the whey protein solution is 15-25% w / w.

[0189] The total amount of protein in the whey protein solution was determined according to Example 1.1.

[0190] Typically, the whey protein solution is prepared by subjecting the whey protein raw material to one or more adjustments that result in a whey protein solution that is supersaturated with BLG.

[0191] Preferably, the raw material is WPC, WPI, SPC, SPI or a combination thereof.

[0192] In the context of the present invention, the term "whey protein material" relates to a composition that is converted into a whey protein solution supersaturated with BLG. Typically, a whey protein material is an aqueous solution comprising non-aggregated BLG, ALA and at least one other whey protein, but typically unsaturated with BLG.

[0193] The embodiments regarding the chemical composition of the whey protein solution are equally applicable to the whey protein raw material. However, typically, at least one parameter of the whey protein raw material is set to avoid supersaturation or at least spontaneous crystallization.

[0194] In some preferred embodiments of the present invention, the supersaturated whey protein solution is prepared by performing one or more adjustments on the whey protein raw material, the adjustments comprising:

[0195] - Adjust pH value;

[0196] - Reduce electrical conductivity;

[0197] - Reduce the temperature;

[0198] - Increase protein concentration;

[0199] - adding an agent that reduces water activity; and

[0200] -Change the ionic composition.

[0201] In some preferred embodiments of the present invention, the preparation of the whey protein solution involves adjusting the pH of the whey protein raw material to 5-6.

[0202] All pH values ​​were measured using a pH glass electrode and normalized to 25 °C.

[0203] For example, the pH of the whey protein solution may be 4.9 to 6.1. For example, the pH of the whey protein solution may be 5.0 to 6.1. Alternatively, the pH of the whey protein solution may be 5.1 to 6.1. Preferably, the pH of the whey protein solution is 5.1 to 6.0.

[0204] In some preferred embodiments of the present invention, the pH of the whey protein solution is 5.0 to 6.0. Preferably, the pH of the whey protein solution is 5.1 to 6.0. More preferably, the pH of the whey protein solution is 5.1 to 5.9. Even more preferably, the pH of the whey protein solution may be 5.2 to 5.9. Most preferably, the pH of the whey protein solution is 5.2 to 5.8.

[0205] Preferably, the pH is adjusted using a food acceptable acid and / or base. Food acceptable acids are particularly preferred, such as carboxylic acids. For example, useful examples of such acids are hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, maleic acid, tartaric acid, lactic acid, citric acid or gluconic acid and / or mixtures thereof.

[0206] In some preferred embodiments of the present invention, a lactone (e.g., D-glucono-δ-lactone) is used to adjust the pH, which slowly hydrolyzes and simultaneously lowers the pH of the aqueous liquid containing it. The target pH after the lactone hydrolysis is completed can be accurately calculated.

[0207] For example, useful examples of food-acceptable bases are hydroxide sources, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, salts of edible acids (eg, trisodium citrate), and / or combinations thereof.

[0208] In another preferred embodiment of the present invention, by adding a cation exchange material (in its H +The pH is adjusted by adding the cation exchange material (in its H form). The magnetic bead / large particle cation exchange material is easily removed from the whey protein solution before or even after crystallization. + Adjusting the pH by adding a precipitate (in the form of a whey protein) is particularly advantageous in the present invention because it lowers the pH without adding negative counterions that would significantly affect the conductivity of the whey protein raw material.

[0209] In some preferred embodiments of the present invention, the preparation of the whey protein solution involves reducing the conductivity of the whey protein raw material.

[0210] Unless otherwise stated, the conductivity values ​​stated herein have been normalized to 25°C.

[0211] The inventors have found that reducing the conductivity of the whey protein solution results in a higher yield of BLG crystals. The minimum achievable conductivity of the whey protein solution depends on the composition of the protein fraction and the lipid fraction (if any). Some protein species, such as casein macropeptide (CMP), contribute more to the conductivity than other protein species. Therefore, preferably, the conductivity of the whey protein raw material is close to the level where the protein and the counter ions of the protein are the main contributors to the conductivity. Generally, the reduction in conductivity involves the removal of at least some small free ions that are present in the liquid phase and are not tightly bound to the protein.

[0212] It is generally preferred that the conductivity of the whey protein solution is at most 10 mS / cm. In some preferred embodiments of the present invention, the conductivity of the whey protein solution is at most 5 mS / cm. Preferably, the conductivity of the whey protein solution is at most 4 mS / cm.

[0213] Lower conductivity is even more preferred, which can result in a higher BLG crystal yield. Therefore, preferably, the whey protein solution preferably has a conductivity of at most 3 mS / cm. In some preferred embodiments of the present invention, the conductivity of the whey protein solution is at most 1 mS / cm. Preferably, the conductivity of the whey protein solution is at most 0.5 mS / cm.

[0214] Preferably, the electrical conductivity of the whey protein raw material is reduced by dialysis or diafiltration. Diafiltration by ultrafiltration is particularly preferred because it allows washing out salts and small charged molecules while retaining protein. In some preferred embodiments of the present invention, the whey protein raw material is subjected to UF / diafiltration and subsequent concentration using the same UF unit.

[0215] The inventors have found that the ratio between the electrical conductivity (expressed in mS / cm) and the total amount of protein in the whey protein solution (expressed in total protein weight % relative to the total weight of the whey protein solution) can advantageously be kept below a certain threshold to promote crystallization of non-aggregated BLG.

[0216] In some preferred embodiments of the present invention, the ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.3. Preferably, the ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.25. Preferably, the ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.20. More preferably, the ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.18. Even more preferably, the ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.12. Most preferably, the ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.10.

[0217] For example, preferably, the ratio between the electrical conductivity of the whey protein solution and the total amount of protein is about 0.07 or even lower.

[0218] In addition, the inventors have found that the whey protein raw material can be advantageously adjusted to provide a whey protein solution having a UF permeate conductivity of at most 10 mS / cm. The UF permeate conductivity is a measure of the conductivity of the small molecule fraction of a liquid. When the term "conductivity" is used as such herein, it refers to the conductivity of the liquid. When the term "UF permeate conductivity" is used, it refers to the conductivity of the small molecule fraction of a liquid, which is measured according to Example 1.14.

[0219] Preferably, the UF osmotic conductivity of the whey protein solution is at most 7 mS / cm. More preferably, the UF osmotic conductivity of the whey protein solution is at most 5 mS / cm. Even more preferably, the UF osmotic conductivity of the whey protein solution may be at most 3 mS / cm.

[0220] Even lower UF permeate conductivity can be used, and if a high yield of non-aggregated BLG is to be obtained, lower UF permeate conductivity is even particularly preferred. Therefore, preferably, the UF permeate conductivity of the whey protein solution is at most 1.0 mS / cm. More preferably, the UF permeate conductivity of the whey protein solution is at most 0.4 mS / cm. Even more preferably, the UF permeate conductivity of the whey protein solution can be at most 0.1 mS / cm. Most preferably, the UF permeate conductivity of the whey protein solution can be at most 0.04 mS / cm.

[0221] For example, if MilliQ water is used as a diluent during diafiltration (the conductivity of MilliQ water is about 0.06 μS / cm), even lower UF permeate conductivity can be achieved. Thus, the UF permeate conductivity of the whey protein solution may be at most 0.01 mS / cm. Alternatively, the UF permeate conductivity of the whey protein solution may be at most 0.001 mS / cm. Alternatively, the UF permeate conductivity of the whey protein solution may be at most 0.0001 mS / cm.

[0222] In some preferred embodiments of the present invention, the preparation of the whey protein solution involves reducing the temperature of the whey protein raw material.

[0223] For example, preparing the whey protein solution may comprise reducing the temperature of the whey protein material to at least 5° C., preferably at least 10° C., even more preferably at least 15° C. For example, preparing the whey protein solution may comprise reducing the temperature of the whey protein material to at least 20° C.

[0224] For example, the temperature of the whey protein raw material may be reduced to at most 30° C., preferably at most 20° C., even more preferably at most 10° C. The inventors have found that even lower temperatures provide higher supersaturation, therefore, the temperature of the whey protein raw material may be reduced, for example, to at most 5° C., preferably at most 2° C., even more preferably at most 0° C. The temperature may even be below 0° C. However, preferably, the whey protein solution should remain pumpable, for example in the form of an ice slurry.

[0225] In some preferred embodiments of the present invention, the whey protein solution is an ice slurry before starting BLG crystallization.Alternatively or additionally, during the BLG crystallization of step b), the crystallized whey protein solution may be converted to or maintained as an ice slurry.

[0226] In some particularly preferred embodiments of the present invention, the preparation of the whey protein solution involves increasing the total protein concentration of the whey protein raw material. For example, the whey protein raw material can be subjected to more than one protein concentration step (e.g., ultrafiltration, nanofiltration, reverse osmosis and / or evaporation) to concentrate the whey protein solution.

[0227] Ultrafiltration is particularly preferred because it allows selective concentration of protein, while the concentrations of salts and carbohydrates are hardly affected. As mentioned above, ultrafiltration is preferably used for diafiltration and concentration of whey protein raw materials.

[0228] In some preferred embodiments of the present invention, the concentration of non-aggregated BLG in the whey protein solution is below the level at which spontaneous crystallization of non-aggregated BLG occurs. Therefore, it is generally preferred that the modification of the whey protein raw material is stopped when the whey protein solution is in the metastable region (i.e., the supersaturated region); wherein, when in the supersaturated region, when using seed crystals, BLG crystals may grow, but crystallization will not start spontaneously.

[0229] In some preferred embodiments of the present invention, the preparation of the whey protein solution involves adding one or more water activity reducing agents to the whey protein raw material.

[0230] Useful but non-limiting examples of such water activity reducing agents are polysaccharides and / or polyethylene glycol (PEG).

[0231] In some preferred embodiments of the invention, the preparation of the whey protein solution involves changing the ionic composition of the whey protein raw material, for example by ion exchange, addition of new ionic species, dialysis or diafiltration.

[0232] Typically, the whey protein solution is prepared by combining two or more of the above-mentioned process steps leading to supersaturation.

[0233] In some preferred embodiments of the present invention, the preparation of the whey protein solution involves at least subjecting the whey protein raw material to:

[0234] - concentration, for example using ultrafiltration, nanofiltration or reverse osmosis at a temperature above 10°C; and

[0235] - Subsequently cooled to a temperature below 10°C.

[0236] In other preferred embodiments of the present invention, the preparation of the whey protein solution involves at least subjecting the whey protein raw material to:

[0237] - Concentration at a pH above 6.0; and

[0238] - followed by addition of an acid (e.g. H + The pH can be lowered by using GDL or cation exchange materials in the form of cation exchange materials.

[0239] In other preferred embodiments of the present invention, the preparation of the whey protein solution involves at least subjecting the whey protein raw material to:

[0240] - Reducing the electrical conductivity, for example by diafiltration using a membrane that retains at least the non-aggregated BLG.

[0241] In other preferred embodiments of the present invention, the preparation of the whey protein solution involves performing at least the following steps on the whey protein raw material:

[0242] - Adjust the pH to 5-6;

[0243] - Reducing the conductivity by diafiltration using a membrane that retains at least non-aggregated BLG;

[0244] - concentrating the protein, for example using ultrafiltration, nanofiltration or reverse osmosis at a temperature above 10°C; and

[0245] - Finally, cooling to a temperature below 10°C.

[0246] In addition, the inventors have found that the yield of non-aggregated BLG in the present method can be increased by controlling the molar ratio between the sum of sodium + potassium and the sum of calcium + magnesium. Unexpectedly, higher relative contents of calcium and magnesium appear to increase the yield of non-aggregated BLG, thereby improving the efficiency of the present method for recovering non-aggregated BLG.

[0247] In some preferred embodiments of the present invention, the molar ratio between Na+K and Ca+Mg of the whey protein solution of step a) is at most 4. More preferably, the molar ratio between Na+K and Ca+Mg of the whey protein solution of step a) is at most 2. Even more preferably, the molar ratio between Na+K and Ca+Mg of the whey protein solution of step a) is at most 1.5, even more preferably at most 1.0. Most preferably, the molar ratio between Na+K and Ca+Mg of the whey protein solution of step a) is at most 0.5, such as at most 0.2.

[0248] The molar ratio between Na+K and Ca+Mg can be calculated as (m Na +m K ) / (m Ca +m Mg ), where m Na is the molar content of Na, m K is the molar content of K, m Ca is the molar content of element Ca, m Mg is the molar content of element Mg.

[0249] Particularly preferably, the whey protein solution has been supersaturated with BLG by salting-in so that non-aggregated BLG can be crystallized from the whey protein solution in salting-in mode.

[0250] In some embodiments of the invention, the whey protein solution has a low content of denatured proteins. This is particularly preferred to avoid aggregated BLG ending up in the ALA-enriched whey protein composition. Preferably, the whey protein solution has a protein denaturation degree of at most 2%, preferably at most 1.5%, more preferably at most 1.0%, most preferably at most 0.8%.

[0251] Step b) of the process involves crystallizing at least some of the non-aggregated BLG of the supersaturated whey protein solution.

[0252] Particularly preferably, the crystallization of step b) is carried out in a salting-out mode, i.e. in a liquid of low ionic strength and conductivity. This is in contrast to a salting-out mode, in which a large amount of salt is added to the solution to induce crystallization.

[0253] For example, the crystallization of non-aggregated BLG in step b) may involve one or more of the following steps:

[0254] - Wait for crystallization to occur;

[0255] - Adding seed crystals;

[0256] - further increase the supersaturation of non-aggregated BLG; and / or

[0257] - Mechanical stimulation.

[0258] In some preferred embodiments of the invention, step b) involves adding seed crystals to the whey protein solution. The inventors have found that adding seed crystals allows the control of the time and location of BLG crystallization to avoid sudden blockage of processing equipment and unexpected stops during production. For example, it is often necessary to avoid the start of crystallization when concentrating whey protein raw materials.

[0259] Particularly preferably, during operation of step b), the whey protein solution does not come into contact with a UF membrane or a MF membrane, unless a ceramic membrane or a high shear system (eg DCF) is employed.

[0260] In principle, any seed material that initiates crystallization of non-aggregated BLG can be used. However, preferably, hydrated BLG crystals or dried BLG crystals are used for seeding to avoid adding other impurities to the whey protein solution.

[0261] When added to the whey protein solution, the seeds may be in dry form or may form part of a suspension. It is currently preferred to add a suspension containing seeds (e.g. BLG crystals) as it appears to cause crystallization to start more quickly. Preferably, such a suspension comprises seeds having a pH of 5-6 and a conductivity of at most 10 mS / cm.

[0262] Particularly preferably, the seeding is performed by a suspension of BLG crystals which have not been dried after BLG crystallization. For example, such a suspension can be a portion of BLG crystals and mother liquor obtained from a previous batch of step 2), or a portion of wet BLG crystals obtained from a previous batch of step 3), step 4) or step 5).

[0263] The inventors have observed that the use of wet BLG crystals as seeds during step 2) provides much larger BLG crystals than the use of dry or poorly hydrated BLG crystals, which again makes the separation of BLG from the mother liquor more efficient. In one experiment (where the whey protein raw material, crystallization conditions, mass and particle size of the seed material, cooling curve and separation method were the same), the inventors found that seeding with non-dried BLG crystals increased the particle size of the resulting crystals by 100% (obtained particle size: 100-130 μm) compared to BLG crystals obtained by seeding with rehydrated, dried BLG crystals (obtained particle size: 40-60 μm).

[0264] Alternatively, if the seeds are based on dried BLG crystals, the crystals are preferably resuspended in an aqueous solution (e.g., water) and the dried BLG crystals are rehydrated for at least 30 minutes, preferably at least 1.0 hour, and even more preferably at least 1.5 hours before the resulting BLG crystal suspension is used to initiate crystallization.

[0265] In some embodiments of the invention, at least some of the seeds are located on a solid phase in contact with the whey protein solution.

[0266] Preferably, the seed crystals have a smaller particle size than the desired BLG crystal size. The size of the seed crystals can be changed by removing the largest seed crystals by sieving or other size fractionation separation methods. For example, the particle size can also be reduced by grinding before particle size fractionation.

[0267] In some embodiments of the invention, at least 90% w / w of the seed crystals have a particle size (measured by sieve analysis) of 0.1 to 600 μm. For example, at least 90% w / w of the seed crystals may have a particle size of 1 to 400 μm. Preferably, at least 90% w / w of the seed crystals may have a particle size of 5 to 200 μm. More preferably, at least 90% w / w of the seed crystals may have a particle size of 5 to 100 μm.

[0268] The particle size and dosage of the seeds can be adjusted to provide optimal crystallization of non-aggregated BLG.

[0269] In some preferred embodiments of the invention, seeds are added to the whey protein material before achieving BLG supersaturation, but preferably in such a way that at least some seeds are still present when supersaturation is achieved. This can be achieved by adding seeds when the whey protein material is close to supersaturation (e.g. during cooling, concentration and / or pH adjustment), and supersaturation is achieved before the seeds are completely dissolved.

[0270] In some preferred embodiments of the present invention, step b) involves further increasing the supersaturation of non-aggregated BLG, preferably to a level that immediately (i.e., within 20 minutes at most, preferably within 5 minutes at most) initiates BLG crystallization. This is also referred to as the nucleation zone, where crystallites spontaneously form and begin the crystallization process.

[0271] For example, supersaturation can be increased by one or more of the following steps:

[0272] - Further increase the protein concentration of the whey protein solution;

[0273] - further cooling the whey protein solution;

[0274] - Make the pH of whey protein solution closer to the optimal pH for BLG crystallization;

[0275] -Further reduce the conductivity.

[0276] In some preferred embodiments of the invention, step b) comprises waiting for BLG crystals to form. This may take several hours, typically for a whey protein solution that is only slightly supersaturated with BLG and to which no seeds are added.

[0277] In some preferred embodiments of the present invention, providing the whey protein solution (step a) and crystallization of non-aggregated BLG (step b) are performed as two separate steps.

[0278] However, in other preferred embodiments of the present invention, step b) involves additional adjustment of the crystallized whey protein solution to increase the supersaturation of non-aggregated BLG, or at least maintain supersaturation. This additional adjustment can increase the yield of BLG crystals.

[0279] Such additional adjustments may involve one or more of the following:

[0280] - further increasing the protein concentration of the crystallized whey protein solution;

[0281] - cooling the crystallized whey protein solution to a lower temperature;

[0282] - Bringing the crystallized whey protein solution closer to the optimal pH for BLG crystallization; and

[0283] - Further reduce the conductivity of the crystallized whey protein solution.

[0284] In some preferred embodiments of the present invention, the crystallized whey protein solution is kept in a metastable zone during step b) to avoid spontaneous formation of new crystals.

[0285] The inventors have determined the lattice structure of isolated BLG crystals by X-ray crystallography, and no similar crystals have been found in the prior art.

[0286] In some preferred embodiments of the present invention, at least some of the BLG crystals obtained during step b) have an orthorhombic space group P 21 21 21.

[0287] Preferably, at least some of the resulting BLG crystals have an orthorhombic space group of P 21 21 21; a unit cell size of The unit cell angle integral angles are α=90°, β=90°, and γ=90°.

[0288] In some preferred embodiments of the present invention, at least some of the resulting BLG crystals have an orthorhombic space group P 2121 21; a unit cell size The unit cell angle integrals are α=90°, β=90°, and γ=90°.

[0289] Even more preferably, at least some of the resulting BLG crystals may have an orthorhombic space group P 21 21 21, a unit cell size The unit cell angle integrals are α=90°, β=90°, and γ=90°.

[0290] Most preferably, at least some of the resulting BLG crystals have an orthorhombic space group of P 21 21 21; a unit cell size of The unit cell angle integrals are α=90°, β=90°, and γ=90°.

[0291] In some particularly preferred embodiments of the present invention, the method comprises step c): separating at least some BLG crystals from the remaining whey protein solution. This is particularly preferred when purification of non-aggregated BLG is desired.

[0292] For example, step c) may comprise separating the BLG crystals to a solid content of at least 30% w / w. Preferably, step c) comprises separating the BLG crystals to a solid content of at least 40% w / w. Even more preferably, step c) comprises separating the BLG crystals to a solid content of at least 50% w / w.

[0293] The inventors have found that high solid content is beneficial for the purification of non-aggregated BLG, because the aqueous portion adhering to the separated BLG crystals usually contains impurities that should be avoided. In addition, high solid content reduces the energy consumption of converting the separated BLG crystals into a dry product (e.g., powder) and increases the yield of non-aggregated BLG obtained from a given capacity drying unit.

[0294] In some preferred embodiments of the present invention, step c) comprises separating the BLG crystals to a solid content of at least 60% w / w. Preferably, step c) comprises separating the BLG crystals to a solid content of at least 70% w / w. Even more preferably, step c) comprises separating the BLG crystals to a solid content of at least 80% w / w.

[0295] In some preferred embodiments of the present invention, the separation in step c) involves one or more of the following operations:

[0296] - Centrifugation;

[0297] - decantation;

[0298] -filter;

[0299] - sedimentation; and

[0300] - A combination of the above operations.

[0301] These unit operations are well known and easily accomplished by those skilled in the art. For example, separation by filtration includes the use of vacuum filtration, dynamic cross-flow filtration (DCF), filter presses, or filter centrifuges.

[0302] Different pore sizes can be used for filtering based on the desired results. Preferably, the filter allows native whey protein and small aggregates to pass but retains BLG crystals. Preferably, the nominal pore size of the filter is at least 0.1 μm. For example, the nominal pore size of the filter is at least 0.5 μm. Even more preferably, the nominal pore size of the filter is at least 2 μm.

[0303] Filters with larger pore sizes can also be used and are in fact preferred if mainly larger crystals should be separated from a liquid containing BLG crystals. In some embodiments of the present invention, the filter has a nominal pore size of at least 5 μm. Preferably, the filter has a nominal pore size of at least 20 μm. Even more preferably, the filter has a nominal pore size of at least 40 μm.

[0304] For example, the pore size of the filter is 0.03-5000 μm (e.g. 0.1-5000 μm). Preferably, the pore size of the filter may be 0.5-1000 μm. Even more preferably, the pore size of the filter may be 5-800 μm, such as 10-500 μm or 50-500 μm.

[0305] In some preferred embodiments of the present invention, the pore size of the filter is 0.03-100 μm. Preferably, the pore size of the filter may be 0.1-50 μm. More preferably, the pore size of the filter may be 4-40 μm. Even more preferably, the pore size of the filter may be 5-30 μm, such as 10-20 μm.

[0306] The use of filters with a pore size of greater than 1 μm has the advantage that bacteria and other microorganisms are at least partially removed during separation and optional washing and / or recrystallization.

[0307] Another advantage of using filters with pore sizes greater than 1 μm is that the removal of water and subsequent drying becomes easier and less energy intensive.

[0308] During the preparation of the whey protein solution, the remaining whey protein solution from which the BLG crystals are separated can be recycled into the whey protein raw material.

[0309] In some preferred embodiments of the present invention, step c) uses a filter centrifuge. In other preferred embodiments of the present invention, step c) uses a decanter centrifuge. Preliminary results show that the use of a filter centrifuge and / or a decanter centrifuge to separate BLG crystals from the mother liquor provides a more robust operating method than, for example, vacuum filtration.

[0310] It is generally preferred to dry the formed filter cake with a drying gas to reduce the moisture content of the filter cake, preferably so that the filter cake can be stripped from the filter. If the filter cake is converted directly into a dry, edible BLG composition, the use of a drying gas may constitute part of the separation step, or may be part of the final drying step.

[0311] In some preferred embodiments of the present invention, step c) employs a DCF unit.

[0312] Initial testing (see Example 6) showed that BLG crystals can be effectively separated using a DCF unit with a membrane pore size of 0.03-5 μm (preferably 0.3-1.0 μm), and the inventors have observed that the DCF unit can be operated for a duration sufficient to separate the crystals from even bulk whey protein solutions containing BLG crystals.

[0313] In some preferred embodiments of the invention, step c) is performed using a DCF unit equipped with a membrane capable of retaining BLG crystals, the DCF permeate is recycled to form part of a whey protein solution or a whey protein raw material, and the DCF retentate can be recovered or returned to the crystallization tank. Preferably, the DCF permeate is treated, for example by ultrafiltration / diafiltration, to supersaturate the BLG before being mixed with the whey protein solution or the whey protein raw material.

[0314] Advantageously, these embodiments do not require raising the temperature of the liquid fluid to above 15°C and are therefore less susceptible to microbial contamination than process variants requiring higher temperatures. Another industrial advantage of these embodiments is that the supersaturation is easily controllable and can be maintained at a level where unwanted spontaneous crystallization does not occur. Therefore, during these process embodiments, the temperature of the liquid fluid is preferably at most 15°C, more preferably at most 12°C, even more preferably at most 10°C, and most preferably at most 5°C.

[0315] These embodiments are illustrated in Example 6 and are described in Figure 6 These embodiments can be implemented in a batch process or a continuous process.

[0316] In some preferred embodiments of the present invention, the method comprises a step of washing the BLG crystals, for example, washing the separated BLG crystals of step c). Washing may comprise a single washing or multiple washing steps.

[0317] Preferably, washing comprises contacting the BLG crystals with a washing liquid without completely dissolving the BLG crystals, and then separating the remaining BLG crystals from the washing liquid.

[0318] Preferably, the wash liquid is selected to avoid complete dissolution of the BLG crystals, for example, the wash liquid may comprise or even consist essentially of deionized water, tap water, or permeate from reverse osmosis.

[0319] For example, the wash liquid may comprise, or even consist essentially of, cold desalinated water, cold tap water, or cold reverse osmosis permeate.

[0320] The pH of the washing liquid may be 5 to 6, preferably 5.0 to 6.0, even more preferably 5.1 to 6.0, such as 5.1 to 5.9.

[0321] Alternatively, the pH of the wash liquor may be 6.1 to 8, preferably 6.4 to 7.6, even more preferably 6.6 to 7.4, for example 6.8 to 7.2. This is typically the pH when the wash liquor is deionized water, tap water or the permeate of reverse osmosis. It is generally preferred that the wash liquor has a low mineral content and a low buffering capacity.

[0322] The conductivity of the washing liquid is at most 0.1 mS / cm, preferably at most 0.02 mS / cm, even more preferably at most 0.005 mS / cm.

[0323] A washing liquid with a lower conductivity may be used. For example, the washing liquid may have a conductivity of at most 1 μS / cm. Alternatively, the washing liquid may have a conductivity of at most 0.1 μS / cm, such as about 0.05 μS / cm.

[0324] Preferably, the washing step is performed at low temperature to limit dissolution of crystallized BLG. The temperature of the washing liquid is preferably at most 30°C, more preferably at most 20°C, even more preferably at most 10°C.

[0325] For example, the washing step may be performed at up to 5° C., more preferably up to 2° C., such as about 0° C. Temperatures below 0° C. may be used as long as the wash liquid does not freeze at that temperature, for example due to the presence of one or more freezing point depressants.

[0326] In some embodiments of the invention, the wash liquor comprises non-aggregated BLG, for example, the amount of non-aggregated BLG is at least 1% w / w (preferably at least 3% w / w, such as 4% w / w).

[0327] Typically, the washing of step d) dissolves at most 80% w / w (preferably at most 50% w / w, even more preferably at most 20% w / w) of the initial amount of BLG crystals. Preferably, the washing of step d) dissolves at most 15% w / w (preferably at most 10% w / w, even more preferably at most 5% w / w) of the initial amount of BLG crystals.

[0328] Typically, the weight ratio between the total amount of washing liquid and the initial amount of separated BLG crystals is at least 1, preferably at least 2, and more preferably at least 5. For example, the weight ratio between the total amount of washing liquid and the initial amount of separated BLG crystals is at least 10. Alternatively, the weight ratio between the total amount of washing liquid and the initial amount of separated BLG crystals is at least 20, such as at least 50 or at least 100.

[0329] The term "total amount of washing liquid" refers to the total amount of washing liquid used during the entire period.

[0330] In some preferred embodiments of the present invention, one or more washing steps are performed in the same filter arrangement as the BLG crystal separation or in a similar filter arrangement. The washing liquid of one or more steps is added to the filter cake containing mainly BLG crystals, which is removed by the filter, while the remaining part of the BLG crystals remains in the filter cake.

[0331] In a particularly preferred embodiment of the present invention, the separation of step c) is performed using a filter that retains BLG crystals. Subsequently, the filter cake is contacted with one or more amounts of washing liquid that pass through the filter cake and the filter. It is generally preferred that each amount of washing liquid is at most 10 times the volume of the filter cake, preferably at most 5 times the volume of the filter cake, more preferably at most 1 times the volume of the filter cake, even more preferably at most 0.5 times the volume of the filter cake, for example at most 0.2 times the volume of the filter cake. The volume of the filter cake includes the solids and fluids (liquids and gases) of the filter cake. Preferably, the filter cake is washed in this way at least 2 times, preferably at least 4 times, even more preferably at least 6 times.

[0332] For example, the spent wash liquid from the washing step may be recycled into the whey protein raw material or whey protein solution, from which the washed non-aggregated BLG may be separated again.

[0333] Furthermore, the method may include a step involving a recrystallization step comprising:

[0334] - dissolving the separated BLG crystals in a recrystallization liquid;

[0335] - Adjust the recrystallization liquid to make BLG supersaturated;

[0336] - crystallizing non-aggregated BLG in a supersaturated, conditioned recrystallization liquid; and

[0337] - Separation of BLG crystals from the remaining conditioned recrystallization liquid.

[0338] The recrystallization may comprise a single recrystallization step or multiple recrystallization steps.

[0339] In some embodiments of the present invention, the BLG crystals of step c) or the subsequently washed BLG crystals are recrystallized at least 2 times. For example, the BLG crystals may be recrystallized at least 3 times, such as at least 4 times.

[0340] The washing and recrystallization steps can be combined in any order and performed multiple times if desired.

[0341] For example, the separated BLG crystals of step c) may be subjected to the following process steps:

[0342] - one or more washing steps; then

[0343] - One or more recrystallization steps.

[0344] Alternatively, the separated BLG crystals of step c) may be subjected to the following process steps:

[0345] - one or more recrystallization steps; then

[0346] - More than one washing step.

[0347] It is also possible to combine a plurality of washing steps and recrystallization steps, for example in the following sequence:

[0348] - one or more washing steps;

[0349] - one or more recrystallization steps;

[0350] - one or more washing steps; and

[0351] - One or more recrystallization steps.

[0352] Or, for example, in the following sequence:

[0353] - one or more recrystallization steps;

[0354] - one or more washing steps;

[0355] - one or more recrystallization steps; and

[0356] - More than one washing step.

[0357] Step d) provides a first composition derived from the recovered mother liquor.

[0358] In the context of the present invention, the terms "first composition derived from the recovered mother liquor" and "first composition" relate to an aqueous liquid composition comprising at least a major portion of the ALA in the recovered mother liquor, preferably comprising substantially all of the ALA in the recovered mother liquor.

[0359] In some embodiments of the invention, the first composition comprises at least 20% (preferably at least 40%, more preferably at least 60%, even more preferably at least 80%, most preferably at least 90%) of the ALA in the recovered mother liquor. Preferably, the first composition comprises substantially all of the ALA in the recovered mother liquor.

[0360] In other preferred embodiments of the present invention, the first composition comprises or even consists of the recycled mother liquor. Thus, it may be preferred that the first composition is the recycled mother liquor itself.

[0361] In other preferred embodiments of the present invention, the first composition is a protein concentrate of the recovered mother liquor.

[0362] In some embodiments of the invention, it is also possible that the first composition comprises one or more other whey protein sources; it is generally preferred that the weight percentage of ALA in the first composition relative to the total amount of protein is at least the same as that of the recovered mother liquor.

[0363] If the recovered mother liquor does not have the desired properties, providing the first composition may, for example, involve subjecting the recovered mother liquor to one or more steps selected from the group consisting of:

[0364] - desalination;

[0365] - Added minerals;

[0366] -dilution;

[0367] -concentrate;

[0368] - Physical reduction of microorganisms; and

[0369] -pH adjustment.

[0370] Non-limiting examples of desalting include, for example, dialysis, gel filtration, UF / diafiltration, NF / diafiltration, and ion exchange chromatography.

[0371] Non-limiting examples of added minerals include adding soluble, edible salts, such as salts of Na, K, Ca and / or Mg. For example, such salts can be phosphates, chlorides, or salts of edible acids, such as citrates, lactobionates, or lactates. Minerals can be added in solid, suspension, or dissolved form.

[0372] Non-limiting examples of dilution include, for example, the addition of a liquid diluent, such as water, desalted water, or an aqueous solution of minerals, acids, or bases.

[0373] Non-limiting examples of concentration include, for example, evaporation, reverse osmosis, nanofiltration, ultrafiltration, and combinations thereof.

[0374] If concentration is necessary to increase the concentration of protein relative to total solids, a concentration step such as ultrafiltration or dialysis is preferably used. If concentration is not necessary to increase the concentration of protein relative to total solids, methods such as evaporation, nanofiltration and / or reverse osmosis may be used.

[0375] Non-limiting examples of physical microbial reduction include, for example, heat treatment, bacterial filtration, ultraviolet radiation, high pressure treatment, pulsed light treatment, pulsed electric field treatment, and ultrasound. These methods are well known to those skilled in the art.

[0376] Typically, bacterial filtration involves microfiltration or macroporous ultrafiltration, requiring a pore size that can retain microorganisms but allow proteins and other target components to pass. Useful pore sizes are typically at most 1.5 μm, preferably at most 1.0 μm, more preferably at most 0.8 μm, even more preferably at most 0.5 μm, and most preferably at most 0.2 μm. The pore size for bacterial filtration is typically at least 0.1 μm.

[0377] For example, bacterial filtration may involve membranes with a pore size of 0.02-1 μm, preferably 0.03-0.8 μm, more preferably 0.04-0.6 μm, even more preferably 0.05-0.4 μm, most preferably 0.1-0.2 μm.

[0378] In some preferred embodiments of the present invention, the liquid to be treated (preferably the mother liquor) is subjected to bacterial filtration and then heat treated using a temperature of up to 80° C. (preferably up to 75° C.) Preferably, the combination of temperature and duration of the heat treatment is selected to provide a sterile liquid.

[0379] In other preferred embodiments of the present invention, the liquid to be treated (preferably the mother liquor) is subjected to bacterial filtration and then heat treated for a duration of at most 0.2 seconds (preferably at most 0.1 seconds) using a temperature of at least 150° C. Preferably, the combination of temperature and duration of the heat treatment is selected to provide a sterile liquid.

[0380] In some preferred embodiments of the invention, physical reduction of microorganisms comprises or even consists of heat treatment.

[0381] Preferably, the heat treatment comprises at least pasteurization.

[0382] In a particularly preferred embodiment, the heat treatment involves heating to a temperature of 70-80°C.

[0383] In some preferred embodiments of the present invention, the heat treatment temperature is 70-80°C, preferably 70-79°C, more preferably 71-78°C, even more preferably 72-77°C, most preferably 73-76°C, for example about 75°C.

[0384] Preferably, when the heat treatment is performed at a temperature of 70 to 80°C, the duration of the heat treatment is from 1 second to 30 minutes. The highest exposure time is most suitable for the lowest temperature range, and vice versa.

[0385] In a particularly preferred embodiment of the present invention, the heat treatment provides a temperature of 70-78°C for 1 second to 30 minutes, more preferably a temperature of 71-77°C for 1 minute to 25 minutes, even more preferably a temperature of 72-76°C for 2 minutes to 20 minutes.

[0386] In some embodiments, higher temperatures may also be preferred, particularly if it is desired to expand and optionally aggregate the non-aggregated BLG prior to drying. For example, the temperature of the heat treatment may be at least 81°C, preferably at least 91°C, more preferably at least 100°C, even more preferably at least 120°C, and most preferably at least 140°C.

[0387] For example, the heat treatment may involve a temperature of 90 to 130° C. and a duration of 4 seconds to 30 minutes. For example, the heat treatment may involve heating to a temperature of 90 to 95° C. for 1 to 10 minutes, such as heating to about 120° C. for about 20 seconds. Alternatively, the heat treatment may involve heating to a temperature of 115 to 125° C. for 5 to 30 seconds, such as heating to about 120° C. for about 20 seconds.

[0388] Alternatively, the heat treatment may be, for example, a UHT type treatment, which generally involves a temperature of 135 to 144° C. and a duration of 2 to 10 seconds.

[0389] Alternatively, but also preferably, the heat treatment may involve a temperature of 145-180°C and a duration of 0.01-2 seconds, more preferably a temperature of 150-180°C and a duration of 0.01-0.3 seconds.

[0390] Thermal treatment may involve the use of conventional equipment, such as plate or tube heat exchangers, scraped surface heat exchangers, or retorting systems. Alternatively, for thermal treatments above 95°C, direct steam-based heating may be particularly preferably employed, for example using direct steam injection, direct steam infusion, or spray cooking. In addition, such direct steam-based heating is preferably used in combination with rapid cooling. Suitable examples of spray cooking may be found in WO2009113858A1, the contents of which are incorporated herein by reference for all purposes. Suitable embodiments of direct steam injection and direct steam infusion may be found in WO2009113858A1 and WO 2010 / 085957A3, the contents of which are incorporated herein by reference for all purposes. For example, general aspects of high temperature treatment may be found in Thermal technologies in food processing ISBN 185573558 X, the contents of which are incorporated herein by reference for all purposes.

[0391] Non-limiting examples of pH adjustment include, for example, the addition of a base and / or acid (preferably a base and / or acid acceptable to food). Particularly preferably, an acid and / or base capable of chelating divalent metal cations is used. Examples of such acids and bases are: EDTA, citric acid, citrate, lactobionic acid, lactobionic acid salts, gluconic acid, gluconate, lactic acid, lactate, phosphoric acid, phosphates, and combinations thereof.

[0392] In some preferred embodiments of the present invention, the pH of the first composition has substantially the same pH as that of the mother solution, and thus preferably has a pH of 5 to 6. Alternatively, the pH of the first composition may be in a pH range other than 5 to 6.

[0393] Preliminary experiments conducted by the inventors have shown that, for example, the recovered mother liquor is generally capable of continuous BLG crystallization if it is concentrated or cooled to a lower temperature. The inventors believe that the recovered mother liquor still contains small crystal fragments that have not been separated in step c) and have therefore been seeded for crystallization. In order to reduce the energy required for drying, the liquid is usually concentrated before drying, but if the recovered mother liquor is used in this way, the concentration will promote the formation of unwanted BLG crystals. The inventors have found that in order to avoid unwanted crystallization and scaling in production, it is beneficial to make the non-aggregated BLG level of the recovered mother liquor below the supersaturation level before drying the product or before concentrating the product.

[0394] Therefore, in some preferred embodiments of the present invention, the BLG in the first composition or the protein concentrate of the first composition is not saturated. Alternatively, the BLG in the first composition or the protein concentrate of the first composition may be supersaturated, as long as it does not contain BLG crystals.

[0395] The pH adjustment of step e) ensures that the first composition or the protein concentrate of the first composition is not supersaturated. If the pH of the first composition or its protein concentrate is between 5.0 and 6.0, the non-aggregated BLG concentration, conductivity and / or temperature are preferably selected to avoid supersaturation.

[0396] In other preferred embodiments of the present invention, the first composition is an ALA isolate of the recovered mother liquor. If so, providing the first composition comprises further ALA enrichment of the recovered mother liquor.

[0397] In the context of the present invention, the term "further ALA enrichment" means that providing a first composition involves one or more process steps, i.e. further ALA enrichment, which provides a first composition having at least 5% higher weight percentage of ALA relative to the total amount of protein compared to the recovered mother liquor.

[0398] Thus, for example, the weight percentage of ALA relative to the total amount of protein in the first composition is at least 5% higher than in the recovered mother liquor. Preferably, the weight percentage of ALA relative to the total amount of protein in the first composition is at least 10% higher, more preferably at least 20% higher, even more preferably at least 30% higher, and most preferably at least 50% higher than in the recovered mother liquor.

[0399] Even higher levels of ALA enrichment may be desired; in some preferred embodiments of the invention, the weight percent of ALA relative to the total amount of protein in the first composition is at least 75% higher than that in the recovered mother liquor. Preferably, the weight percent of ALA relative to the total amount of protein in the first composition is at least 100% higher, more preferably at least 150% higher, even more preferably at least 200% higher, and most preferably at least 400% higher, compared to the recovered mother liquor.

[0400] The weight percentage of ALA in the first composition depends on how the mother liquor is processed to obtain the first composition, but is generally at least 20% w / w relative to the total amount of protein. Preferably, the weight percentage of ALA in the first composition relative to the total amount of protein is at least 25% w / w. More preferably, the weight percentage of ALA in the first composition relative to the total amount of protein is at least 30% w / w. Even more preferably, the weight percentage of ALA in the first composition relative to the total amount of protein is at least 40% w / w. Most preferably, the weight percentage of ALA in the first composition relative to the total amount of protein is at least 50% w / w.

[0401] The inventors anticipate that if the whey protein raw material is a whey protein source free of CMP (e.g. whey protein isolate separated from acid whey or milk albumin) and DCF is used as described in Example 5, a weight percentage of ALA greater than 60% relative to the total amount of protein can be obtained.

[0402] Thus, in some preferred embodiments of the present invention, the weight percentage of ALA relative to the total amount of protein in the first composition is at least 60% w / w. More preferably, the weight percentage of ALA relative to the total amount of protein in the first composition is at least 70% w / w. Even more preferably, the weight percentage of ALA relative to the total amount of protein in the first composition is at least 80% w / w. Most preferably, the weight percentage of ALA relative to the total amount of protein in the first composition is at least 90% w / w.

[0403] Further enrichment of ALA may be performed by any suitable method.

[0404] In some preferred embodiments of the invention, further enrichment of ALA involves type A enrichment, which involves adjusting the pH to 3.5-5.5 and heating to 50-70°C to form reversible aggregation of ALA, followed by recovery of the aggregated ALA. The ALA recovered by this process will then form part of the first fraction. Useful examples of such methods for further enrichment of ALA are described in U.S. Pat. No. 5,455,331 (Pearce et al.), U.S. Pat. No. 6,613,377, and Muller et al. (Lait 83, pp. 439-451, 2003), the contents of which are incorporated herein by reference for all purposes.

[0405] In some preferred embodiments of the invention, further enrichment of ALA involves type B enrichment, which involves subjecting the recovered mother liquor to ion exchange chromatography. Useful examples of such methods for further enrichment of ALA are described in de Jongh et al. (Mild Isolation Procedure Discloses New Protein Structural Properties of β-Lactoglobulin, J Dairy Sci. 2001, 84(3): 562-571) and Vyas et al. (Scale-Up of Native β-Lactoglobulin Affinity Separation Process, J. Dairy Sci. 2002, 85: 1639-1645), the contents of which are incorporated herein by reference for all purposes.

[0406] In some preferred embodiments of the invention, further enrichment of ALA involves type C enrichment using membrane separation to separate ALA from other whey proteins. A useful example of such a method for further enrichment of ALA is described in US 5,008,376, the contents of which are incorporated herein by reference for all purposes.

[0407] In some preferred embodiments of the invention, further enrichment of ALA involves type D enrichment to remove CMP from ALA and other whey proteins using ultrafiltration at a pH of up to pH 4. Useful embodiments and examples of acidic ultrafiltration steps are described in WO2014076252A1, WO9929183A1 and US5278288, the contents of which are incorporated herein by reference for all purposes.

[0408] For example, further enrichment of ALA may involve a combination of two or more enrichment processes selected from Type A, Type B, Type C, and Type D.

[0409] In some preferred embodiments of the present invention, the first composition comprises at least 92% w / w ALA relative to the total amount of protein, preferably at least 95% w / w, more preferably at least 97% w / w, even more preferably at least 98%, and most preferably at least 99.5% w / w of non-aggregated BLG relative to the total amount of protein.

[0410] In some preferred embodiments of the present invention, the first composition comprises a total amount of protein of at least 5% w / w, preferably at least 10% w / w, more preferably at least 15% w / w, even more preferably at least 20%, most preferably at least 30% w / w.

[0411] In some preferred embodiments of the present invention, the first composition comprises a total amount of protein of 5-40% w / w, preferably 10-35% w / w, more preferably 15-30% w / w, even more preferably 20-25% w / w.

[0412] The inventors have observed that increasing protein concentration in the first composition gives a spray-dried powder with a higher bulk density and therefore it is preferred to have a relatively high protein concentration in the first composition.

[0413] Therefore, in other preferred embodiments of the present invention, the first composition comprises a total protein amount of 10-40% w / w, preferably 20-38% w / w, more preferably 24-36% w / w, even more preferably 28-34% w / w.

[0414] In some preferred embodiments of the present invention, the first composition comprises a total solid content of 5-50% w / w, preferably 10-40% w / w, more preferably 15-35% w / w, even more preferably 20-30% w / w.

[0415] In some preferred embodiments of the present invention, the first composition comprises water at a content of 50-95% w / w, preferably 60-90% w / w, more preferably 65-85% w / w, even more preferably 70-80% w / w.

[0416] In some preferred embodiments of the present invention, the first composition comprises carbohydrates in an amount of at most 60% w / w, preferably at most 50% w / w, more preferably at most 20% w / w, even more preferably at most 10% w / w, even more preferably at most 1% w / w, most preferably at most 0.1% w / w. For example, the first composition may comprise carbohydrates such as lactose, oligosaccharides and / or hydrolysates of lactose (i.e. glucose and galactose), sucrose and / or maltodextrin.

[0417] In some preferred embodiments of the present invention, the first composition comprises lipid in an amount of at most 10% w / w, preferably at most 5% w / w, more preferably at most 2% w / w, even more preferably at most 0.1% w / w.

[0418] The present inventors have discovered that it may be beneficial to control the mineral content to achieve certain desired properties of the first composition.

[0419] In some preferred embodiments of the present invention, the total amount of Na, K, Mg and Ca of the first composition is at most 10 mmol / g protein. Preferably, the total amount of Na, K, Mg and Ca of the first composition is at most 6 mmol / g protein, more preferably at most 4 mmol / g protein, even more preferably at most 2 mmol / g protein.

[0420] In other preferred embodiments of the present invention, the total amount of Na, K, Mg and Ca of the first composition is at most 1.0 mmol / g protein. Preferably, the total amount of Na, K, Mg and Ca of the first composition is at most 0.6 mmol / g protein, more preferably at most 0.4 mmol / g protein, even more preferably at most 0.2 mmol / g protein. Most preferably, it is at most 0.1 mmol / g protein.

[0421] In other preferred embodiments of the present invention, the total amount of Mg and Ca of the first composition is at most 5 mmol / g protein. Preferably, the total amount of Mg and Ca of the first composition is at most 3 mmol / g protein, more preferably at most 1.0 mmol / g protein, even more preferably at most 0.5 mmol / g protein.

[0422] In other preferred embodiments of the present invention, the total amount of Mg and Ca of the first composition is at most 0.3 mmol / g protein. Preferably, the total amount of Mg and Ca of the first composition is at most 0.2 mmol / g protein, more preferably at most 0.1 mmol / g protein, even more preferably at most 0.03 mmol / g protein, most preferably at most 0.01 mmol / g protein.

[0423] For certain applications, it is necessary to change the pH of the first composition in order to obtain a product with suitable properties. In such embodiments, the method of the invention comprises step e).

[0424] Therefore, in some preferred embodiments of the present invention, the method comprises step e), wherein:

[0425] - adjusting the pH of the first composition to 2.5 to 4.9, preferably 2.8 to 4.5, more preferably 2.8 to 3.2, or

[0426] - The pH of the first composition is adjusted to 6.1 to 8.5, preferably 6.3 to 8.0, even more preferably 6.5 to 7.5.

[0427] For example, the pH of the first composition may be adjusted to 2.5 to 4.9, preferably 2.8 to 4.5, and more preferably 2.8 to 3.2.

[0428] Alternatively, the pH of the first composition may be adjusted to 6.1 to 8.5, preferably 6.3 to 8.0, more preferably 6.5 to 7.5.

[0429] Preferably, pH adjustment is performed with one or more of the food grade acids and bases described herein, and if a strong acid or base is used, it is preferably performed with a dilute acid or dilute base.

[0430] Step f) involves drying:

[0431] - the first composition obtained from step d) or its protein concentrate; or

[0432] - The pH adjusted first composition or its protein concentrate obtained from step e).

[0433] The drying of step f) typically comprises spray drying or freeze drying.

[0434] In some preferred embodiments of the present invention, the liquid fluid subjected to drying is the pH adjusted protein concentrate of the first composition.

[0435] The term "liquid fluid to be dried" is one of the following liquids:

[0436] - a first composition obtained from step d);

[0437] - a protein concentrate of the first composition obtained in step d);

[0438] - the pH adjusted first composition obtained from step e); or

[0439] - The pH adjusted protein concentrate of the first composition obtained from step e).

[0440] In other preferred embodiments of the present invention, the liquid fluid to be dried is a protein concentrate of the first composition.

[0441] Spray drying is the currently preferred drying method.

[0442] In some embodiments of the present invention, when reaching the outlet of the spray device (e.g., a nozzle or an atomizer), the temperature of the liquid fluid to be dried is at most 70° C., preferably at most 60° C., more preferably at most 50° C. In some preferred embodiments of the present invention, when reaching the outlet of the spray device, the temperature of the liquid fluid to be dried is at most 40° C., preferably at most 30° C., more preferably at most 20° C., even more preferably at most 10° C., most preferably at most 5° C.

[0443] The spray device of a spray dryer is, for example, a nozzle or an atomizer, which converts the solution or suspension to be dried into droplets which enter the drying chamber of the spray dryer.

[0444] Particularly preferably, the temperature of the liquid fluid to be dried is 0-50°C, preferably 2-40°C, more preferably 4-35°C, most preferably 5-10°C when reaching the outlet of the spray device.

[0445] The inlet temperature of the gas of the spray dryer is preferably 140-220° C., more preferably 160-200° C., even more preferably 170-190° C., for example, preferably about 180° C. The outlet temperature of the gas of the spray dryer is preferably 50-95° C., more preferably 70-90° C., even more preferably 80-88° C., for example, preferably about 85° C. According to experience, it is considered that the solid to be spray-dried is heated to a temperature 10-15° C. lower than the gas outlet temperature.

[0446] In some preferred embodiments of the present invention, the spray dryer is preferably 50-85°C, more preferably 60-80°C, even more preferably 65-75°C, for example preferably about 70°C.

[0447] Furthermore, the drying step may comprise fluidized bed drying, for example integrated in the spray drying apparatus, or carried out as a separate unit after spray drying.

[0448] The combination of spray drying and fluidized bed drying makes it possible to reduce the amount of water removed when the droplets to be dried move in the spray drying chamber, while the residual water is removed from the wet powder by fluidized bed drying. Compared with drying by spray drying alone, this scheme requires less energy for drying, and also makes it possible to modify the powder by, for example, instantization and / or agglomeration. Preferably, instantization is performed by applying lecithin or another useful wetting agent to the surface of the powder. When instantization is performed, the amount of instantization agent (e.g., lecithin) dissolved in edible oil is generally 0.5-2% w / w, preferably 1.0-1.5% w / w, relative to the total weight of the final powder.

[0449] The present inventors have noted that the crystallization process (including the preparation of whey protein solutions) is prone to microbial growth and have found that it would be beneficial to improve the process to address this problem.

[0450] Particularly preferably, the total time that the ALA molecules are exposed to a temperature above 12°C, from the provision of the whey protein raw material to the drying in step f) or the subsequent use of the ALA in food production, is at most 24 hours, preferably 20 hours, more preferably at most 12 hours, even more preferably at most 6 hours, most preferably at most 3 hours.

[0451] It is possible, and often preferred, to reduce the duration further; thus, in certain preferred embodiments of the invention, the total time that the ALA molecules are at a temperature above 12°C, from the provision of the whey protein raw material to the drying of step f) or the subsequent use of the ALA in food production, is at most 2 hours, preferably 1 hour, more preferably at most 0.5 hours, even more preferably at most 0.3 hours, most preferably at most 0.1 hours.

[0452] Furthermore, preferably, the method comprises at least one physical reduction microorganism, which is preferably applied to the mother liquor after the removal of the BLG crystals, and / or to the liquid fluid comprising ALA after step c).

[0453] Preferably, physically reducing microorganisms comprises one or more of the following steps:

[0454] - heat treatment, preferably at least pasteurization;

[0455] - UV radiation treatment;

[0456] - Pulsed light treatment;

[0457] - Pulsed electric field treatment;

[0458] - microfiltration;

[0459] - high pressure treatment; and

[0460] - Sonication.

[0461] These processes are well known to those skilled in the art and further details regarding heat treatment are provided herein.

[0462] Physical reduction of microorganisms involving microfiltration requires a pore size that retains the microorganisms but allows proteins and other target components to pass through. Useful pore sizes are typically at most 1.5 μm, preferably at most 1.0 μm, more preferably at most 0.8 μm, even more preferably at most 0.5 μm, and most preferably at most 0.2 μm. The pore size for bacterial filtration is typically at least 0.1 μm.

[0463] Preferably, the liquid fluid subjected to drying has a low content of microorganisms. In some embodiments of the invention, the liquid fluid subjected to drying comprises at most 500.000 CFU / g, preferably at most 100.000 CFU / g, more preferably at most 50.000 CFU / g, even more preferably at most 10.000 CFU / g.

[0464] Preferably, the liquid fluid being dried may include up to 1000 colony-forming units (CFU, colony-forming unit) / g. Even more preferably, the liquid fluid being dried includes up to 600CFU / g. More preferably, the liquid fluid being dried includes up to 300CFU / g. Even more preferably, the liquid fluid being dried includes up to 100CFU / g. Even more preferably, the liquid fluid being dried includes up to 50CFU / g. Most preferably, the liquid fluid being dried includes up to 20CFU / g, for example, up to 10CFU / g. In a particularly preferred embodiment, the liquid fluid being dried is sterile. For example, the liquid fluid being dried can be prepared by combining several physical microbial reduction processes during the drying of the liquid fluid.

[0465] The method generally includes the step of packaging an edible ALA-enriched whey protein composition. Typically, the edible whey protein composition is packaged in a suitable container, which is then closed and / or sealed. For example, packaging can be performed under aseptic or sterile conditions, such as filling and sealing the edible whey protein composition into a sterile container.

[0466] Another aspect of the invention relates to an edible ALA-enriched whey protein composition, such as obtainable by the methods described herein.

[0467] In some preferred embodiments of the present invention, the edible ALA-enriched whey protein composition comprises:

[0468] - ALA in an amount of 24 to 80% w / w, preferably 24 to 70% w / w, relative to the total amount of protein;

[0469] - 3-14% w / w immunoglobulin relative to the total protein; and

[0470] - Optionally, a phospholipid content of 1-6% w / w, preferably 2-5% w / w, relative to the total amount of protein.

[0471] The phospholipid content was measured according to Vaghela et al. (Vaghela et al., Quantitative analysis of phospholipids from whey protein concentrates by high-performance liquid chromatography with an arrow-bore column and an evaporative light-scattering detector, American Oil Chemists' Society 1995, 72(6): 729-733).

[0472] For example, when the whey protein raw material is a serum protein concentrate that has not been heat-treated for protein denaturation, such an edible ALA-enriched whey protein composition can be obtained.

[0473] The inventors have found that being able to provide an edible ALA-enriched whey protein composition comprising immunoglobulins in addition to ALA and optionally also phospholipids is particularly advantageous as these components may be used in paediatric nutrition.

[0474] In some embodiments of the invention, the edible ALA-enriched whey protein composition comprises up to 15% w / w caseins relative to the total amount of protein.

[0475] In some preferred embodiments of the present invention, the ALA-enriched whey protein composition may comprise:

[0476] - 40-70% w / w ALA relative to the total protein;

[0477] - up to 15% w / w caseins relative to the total amount of protein; and

[0478] - At least 3% w / w immunoglobulins relative to the total amount of protein.

[0479] An advantage of the present invention is that the ALA-enriched whey protein composition obtained is generally very gently processed and not subjected to excessive heat stress. In some preferred embodiments of the present invention, the furosine value of the ALA-enriched whey protein composition is at most 50 mg / 100 g protein. Preferably, the furosine value of the ALA-enriched whey protein composition is at most 30 mg / 100 g protein. More preferably, the furosine value of the ALA-enriched whey protein composition is at most 20 mg / 100 g protein. Even more preferably, the furosine value of the ALA-enriched whey protein composition is at most 10 mg / 100 g protein. Most preferably, the furosine value of the ALA-enriched whey protein composition is at most 2 mg / 100 g protein, preferably with no detectable furosine value at all.

[0480] Typically, the content of BLG in an ALA-enriched whey protein composition is relatively low. In some preferred embodiments of the present invention, the ALA-enriched whey protein composition comprises up to 40% w / w of BLG relative to the total amount of protein. Preferably, the ALA-enriched whey protein composition comprises up to 30% w / w of BLG relative to the total amount of protein. More preferably, the ALA-enriched whey protein composition comprises up to 20% w / w of BLG relative to the total amount of protein. Even more preferably, the ALA-enriched whey protein composition comprises up to 10% w / w of BLG relative to the total amount of protein. Most preferably, the ALA-enriched whey protein composition comprises up to 2% w / w of BLG relative to the total amount of protein. For example, preferably, the ALA-enriched whey protein composition comprises up to 0.5% w / w of BLG relative to the total amount of protein.

[0481] Another aspect of the present invention relates to a method for producing a food product, the method comprising the steps of:

[0482] a) providing a whey protein solution, the whey protein solution comprising non-aggregated BLG, ALA and optionally other whey proteins, the whey protein solution being supersaturated with BLG and having a pH of 5 to 6;

[0483] b) crystallizing non-aggregated BLG in a supersaturated whey protein solution, preferably in a salting-in mode; and

[0484] c) separating the BLG crystals from the remaining mother liquor and recovering at least some of the mother liquor;

[0485] d) providing a first composition, said first composition being derived from the recovered mother liquor and optionally the spent wash liquor;

[0486] e) Optionally, adjusting the pH of the first composition to:

[0487] i) pH 2.5 to 4.9; or

[0488] ii) pH 6.1 to 8.5;

[0489] f) optionally, drying the first composition or its protein concentrate obtained from step d); or drying the pH adjusted first composition or its protein concentrate obtained from step e);

[0490] g) mixing the following components with one or more ingredients and converting the obtained mixture into a food product:

[0491] g1) the first composition obtained from step d) or a protein concentrate thereof;

[0492] g2) the pH adjusted first composition or its protein concentrate obtained from step e); and / or

[0493] g3) The dried composition obtained from step f).

[0494] The food product is an infant formula, a beverage, an instant beverage powder, a protein bar, porridge or a smoothie.

[0495] One or more ingredients used to prepare food products typically include one or more non-dairy carbohydrates, non-dairy lipids and / or non-dairy proteins. The term "non-dairy carbohydrates" refers to carbohydrates that are not present in cow's milk. The term "non-dairy lipids" refers to lipids that are not present in cow's milk. The term "non-dairy carbohydrates" refers to proteins that are not present in cow's milk.

[0496] The amino acid profile of the ALA-enriched whey protein composition is particularly suitable for infant formula and other pediatric food products.

[0497] Yet another aspect of the present invention relates to a food product, preferably a nutritional product, comprising a whey protein composition enriched with ALA, such as obtainable by the above method.

[0498] Another aspect of the present invention relates to a nutritional product comprising an ALA-enriched whey protein composition as described herein.

[0499] In the context of the present invention, the term "nutritional product" relates to an edible product (i.e. a product that is safe for human consumption) comprising at least protein and one or more of the following: lipids, carbohydrates, minerals and vitamins. The nutritional product preferably comprises protein, carbohydrates and lipids, and even more preferably comprises protein, carbohydrates, lipids, minerals and vitamins.

[0500] In some preferred embodiments of the present invention, the nutritional product is a nutritional product suitable for clinical nutrition, a nutritional product suitable for sports nutrition, or a nutritional product suitable for pediatric nutrition.

[0501] Particularly preferably, the nutritional product is a pediatric nutritional product. Preferably, the nutritional product is a nutritionally complete infant formula or an infant formula base, which contains at least the proteins required for an infant formula. Alternatively, but also preferably, the pediatric nutritional product may be a follow-up formula or a growing-up milk.

[0502] In some preferred embodiments of the invention, the nutritional product (e.g. in the form of an infant formula) comprises:

[0503] - at least 40% w / w, preferably at least 45% w / w ALA relative to the total amount of protein; and

[0504] - At least 5% w / w immunoglobulins relative to the total amount of protein.

[0505] In other embodiments of the invention, the nutritional product (e.g. in the form of an infant formula) comprises:

[0506] - 40-70% w / w ALA relative to the total protein;

[0507] - up to 15% w / w caseins relative to the total amount of protein; and

[0508] - At least 5% w / w immunoglobulin.

[0509] In some preferred embodiments of the invention, the nutritional product (e.g. in the form of an infant formula) comprises:

[0510] - ALA in an amount of 24 to 80% w / w, preferably 40 to 70% w / w, more preferably 45 to 65% w / w, relative to the total amount of protein;

[0511] - Immunoglobulins in an amount of 5 to 14% w / w relative to the total amount of protein;

[0512] - Optionally, a phospholipid content of 1-6% w / w, preferably 2-5% w / w, relative to the total amount of protein.

[0513] In some embodiments of the invention, the nutritional product (e.g. in the form of an infant formula) comprises up to 50% w / w caseins relative to the total amount of protein, preferably up to 40% w / w caseins, most preferably up to 30% w / w caseins.

[0514] In some preferred embodiments of the invention, the nutritional product (e.g. in the form of an infant formula) comprises:

[0515] - 24-50% w / w ALA relative to the total protein;

[0516] - 20-40% w / w caseins relative to the total protein content;

[0517] - At least 3-15% w / w immunoglobulin relative to the total amount of protein.

[0518] The content of BLG in nutritional products (e.g., in the form of infant formula) is generally relatively low. In some preferred embodiments of the present invention, the nutritional product (e.g., in the form of infant formula) comprises up to 40% w / w BLG relative to the total amount of protein. Preferably, the nutritional product (e.g., in the form of infant formula) comprises up to 30% w / w BLG relative to the total amount of protein. More preferably, the nutritional product (e.g., in the form of infant formula) comprises up to 20% w / w BLG relative to the total amount of protein. Even more preferably, the nutritional product (e.g., in the form of infant formula) comprises up to 10% w / w BLG relative to the total amount of protein. Most preferably, the nutritional product (e.g., in the form of infant formula) comprises up to 2% w / w BLG relative to the total amount of protein. For example, the nutritional product (e.g., in the form of infant formula) comprises up to 0.5% w / w BLG relative to the total amount of protein.

[0519] The one or more other ingredients that may be included in the nutritional product may advantageously be selected from ingredients commonly used in pediatric products.

[0520] For example, a nutritional product (e.g., in the form of an infant formula) may include at least one human milk oligosaccharide (HMO), such as 2'-FL and LNnT. Studies have shown that HMOs have multiple effects in improving central nervous system (CNS) function. In certain aspects, in addition to including at least one of the above-mentioned 2'-FL and LNnT, the nutritional product also includes other sialylated or fucosylated human milk oligosaccharides (HMO).

[0521] Any or all of the HMOs used in the nutritional products may be isolated or enriched from milk secreted by mammals, including but not limited to human, bovine, ovine, porcine or caprine species. HMOs may also be produced by microbial fermentation, enzymatic processes, chemical synthesis or a combination thereof.

[0522] For example, suitable sialylated HMOs for inclusion in infant formula may comprise at least one sialic acid residue, for example, in the oligosaccharide backbone. In certain aspects, the sialylated HMO comprises two or more sialic acid residues.

[0523] Alternatively or additionally, the nutritional product may also comprise other types of oligosaccharides, such as trans-galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS) and / or polydextrose.

[0524] Nutritional products (e.g. in the form of infant formula) may also contain one or more polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA), arachidonic acid (AA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), linoleic acid, linolenic acid (alpha linolenic acid) and gamma-linolenic acid.

[0525] Research has shown that PUFAs play multiple roles in supporting the brain and vision development of infants. Applicants believe that including DHA and AA in infant formula may improve neurological functions such as cognition, learning and memory related to the CNS.

[0526] In certain aspects, PUFAs are provided as free fatty acids in the form of triglycerides, diglycerides, monoglycerides, phospholipids, or mixtures of more than one of the above (preferably in the form of triglycerides). PUFAs can be derived from oil sources, such as vegetable oils, marine plankton, fungal oils, and fish oils. In certain aspects, PUFAs are derived from fish oils, such as herring oil, salmon oil, anchovy oil, cod oil, halibut oil, tuna oil, or menhaden oil.

[0527] The nutritional product (e.g. in the form of an infant formula) may also comprise more than one nucleotide, including, for example, the nucleotides inosine monophosphate, cytidine 5'-monophosphate, uridine 5'-monophosphate, adenosine 5'-monophosphate, guanosine 5'-1-monophosphate, more preferably cytidine 5'-monophosphate, uridine 5'-monophosphate, adenosine 5'-monophosphate and guanosine 5'-monophosphate.

[0528] For example, the carbohydrate concentration of a nutritional product (e.g., in the form of an infant formula) can be about 5% to about 40% w / w of the nutritional product weight, including about 7% to about 30%, including about 10% to about 25%. When present, by weight of infant formula, fat concentration is most typically about 1% to about 30% of infant formula weight, including about 2% to about 15%, and also including about 3% to about 10%. When present, protein concentration is most typically about 0.5% to about 30% of the nutritional product weight, including about 1% to about 15%, and also including about 2% to about 10%.

[0529] In some embodiments of the invention, in addition to the above-mentioned PUFAs, the nutritional product (e.g., in the form of an infant formula) also includes a fat source. Suitable fat sources for use herein include any fat or fat source that is suitable for use in oral infant formula and is compatible with the basic ingredients and characteristics of the formula.

[0530] Other non-limiting examples of suitable fats or sources thereof for use in the nutritional products described herein include coconut oil, fractionated coconut oil, soybean oil, corn oil, olive oil, safflower oil, high oleic safflower oil, oleic acid (EMERSOL 6313 OLEICACID, Cognis Oleochemicals, Malaysia), MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm oil and palm kernel oil, palm olein, rapeseed oil, marine oils, fish oils, fungal oils, algae oils, cottonseed oil, and combinations thereof.

[0531] In addition to whey protein and casein, the nutritional product may also include other types of proteins. Suitable proteins for nutritional products (e.g., in the form of infant formula) or non-limiting examples of their sources include hydrolyzed, partially hydrolyzed or non-hydrolyzed proteins or protein sources, which may be from any known or other suitable sources, such as animals (e.g., meat, fish), cereals (e.g., rice, corn), vegetables (e.g., soybeans), or combinations thereof. Non-limiting examples of such proteins include highly hydrolyzed casein, soy protein isolate, and soy protein concentrate.

[0532] For example, the nutritional product may include hydrolyzed protein, i.e., protein hydrolysate. In this article, the terms "hydrolyzed protein" or "protein hydrolysate" are used interchangeably, including highly hydrolyzed proteins, wherein the degree of hydrolysis is most typically at least about 20%, including about 20% to about 80%, also including about 30% to about 80%, and even more preferably about 40% to about 60%. The degree of hydrolysis is the degree to which peptide bonds are broken by a hydrolysis process. To characterize the highly hydrolyzed protein components of these embodiments, the protein hydrolysis degree can be easily determined by a person of ordinary skill in the field of formulations by the ratio of amino nitrogen to total nitrogen (AN / TN) of the protein components of the quantitatively selected liquid formulations. The amino nitrogen component is determined by quantitative determination of amino nitrogen content by USP titration, and the total nitrogen component is determined by the Tecator Kjeldahl method, all of which are methods well known to a person of ordinary skill in the field of analytical chemistry.

[0533] Suitable hydrolyzed proteins include soy protein hydrolysates, casein protein hydrolysates, whey protein hydrolysates, rice protein hydrolysates, potato protein hydrolysates, fish protein hydrolysates, egg white hydrolysates, gelatin protein hydrolysates, combinations of animal and plant protein hydrolysates, and combinations thereof. Particularly preferred protein hydrolysates include whey protein hydrolysates and hydrolyzed sodium caseinate.

[0534] Except lactose, nutrition product also can comprise other carbohydrates.The limiting examples of suitable carbohydrate or its source include: maltodextrin, starch or corn starch of hydrolysis or modification, glucose polymer, corn syrup, corn syrup solids, carbohydrate in rice source, carbohydrate in pea source, carbohydrate in potato source, tapioca, sucrose, fructose, lactose, high fructose corn syrup, honey, sugar alcohol (such as maltitol, erythritol, sorbitol), artificial sweetener (such as sucralose, acesulfame potassium, stevioside) and their combination.The carbohydrate that is particularly desired is the maltodextrin of low glucose equivalent (DE).

[0535] Typically, the casein source is added to the ALA-enriched whey protein composition in an amount sufficient to obtain the desired weight ratio between casein and whey protein in the nutritional product. In some preferred embodiments of the present invention, the ALA-enriched whey protein composition and the casein source are mixed so that the weight ratio between whey protein and casein is 1 to 9, preferably 1 to 3, even more preferably 1.2 to 1.9, such as about 1.5.

[0536] In the context of the present invention, the weight ratio between the two components A and B is determined as the weight of component A divided by the weight of component B. Thus, if a composition comprises 9% w / w of A and 6% w / w of B, the weight ratio is 9% / 6%=1.5.

[0537] The advantage of the present method is that the present method crystallizes non-aggregated BLG much faster than comparable methods of the prior art. The duration from initial conditioning of the whey protein raw material to completion of the separation of step c may be at most 10 hours, preferably at most 4 hours, more preferably at most 2 hours, even more preferably at most 1 hour.

[0538] Example

[0539] Example 1 - Analytical Methods

[0540] Example 1.1: Determination of total protein amount

[0541] The total amount of protein (true protein) in the sample was determined as follows:

[0542] 1) Determine the total nitrogen content of the sample according to ISO 8968-1 / 2 | IDF 020-1 / 2 - Milk - Determination of nitrogen content - Part 1 / 2: Determination of nitrogen content using the Kjeldahl method;

[0543] 2) Determination of non-protein nitrogen in the sample according to ISO 8968-4 | IDF 020-4 - Milk - Determination of nitrogen content - Part 4: Determination of non-protein-nitrogen content; and

[0544] 3) Calculate the total amount of protein (m 总氮 -m 非蛋白氮 )*6.38.

[0545] Example 1.2: Determination of non-aggregated BLG, ALA and CMP

[0546] The contents of non-aggregated α-lactalbumin (ALA), β-lactoglobulin (BLG) and casein macropeptide (CMP) were analyzed by HPLC at 0.4 mL / min. 25 μL of the filtered sample was injected into 2 TSKgel3000PWxl (7.8 mm 30 cm, Tosohass, Japan) chromatographic columns, which were connected in series with an attached pre-packed column PWxl (6 mm × 4 cm, Tosohass, Japan) equilibrated with an eluent (composed of 465 g Milli-Q water, 417.3 g acetonitrile and 1 mL trifluoroacetic acid), using a UV detector at 210 nm.

[0547] The peak area of ​​the corresponding standard protein was compared with the peak area of ​​the sample to determine the native α-lactalbumin (C α ), β-lactoglobulin (C β ) and casein macropeptide (C CMP ) content was quantitatively determined.

[0548] The total amount of other proteins (non-BLG proteins) was determined by subtracting the amount of BLG from the total amount of protein (determined according to Example 1.1).

[0549] Example 1.3: Determination of turbidity

[0550] Turbidity is the cloudiness or haziness of a fluid caused by large numbers of particles that are not normally visible to the naked eye, similar to smoke in the air.

[0551] Turbidity is measured in Nephelometric Turbidity Units (NTU).

[0552] Add 20mL of beverage / sample into the NTU glass and place 3000 IR turbidity meter. Measure the NTU value after stabilization and repeat twice.

[0553] Example 1.4: Determination of viscosity

[0554] The viscosity of the beverage formulations was measured using a rheometer (Anton Paar, Physica MCR301).

[0555] Add 3.8 mL of sample to cup DG26.7. Equilibrate the sample to 22°C and then -1 Preshear for 30 seconds, followed by 30 seconds of equilibration, and 1 second -1 Up to 200s -1 To 1s -1 The shear rate was scanned.

[0556] Unless otherwise stated, viscosities are expressed in 100s. -1 The higher the cP value measured, the lower the viscosity.

[0557] Alternatively, viscosity was estimated using a Gilson Viscoman with a shear rate of approximately 300 s -1 .

[0558] Example 1.5: Determination of ash content

[0559] The ash content of food products is determined according to NMKL 173:2005 "Ash, gravimetric determination in foods".

[0560] Example 1.6: Determination of conductivity

[0561] The "conductivity" (sometimes referred to as "specific conductance") of an aqueous solution is a measure of the ability of a solution to conduct electricity. For example, conductivity can be determined by measuring the AC resistance of a solution between two electrodes, with the result usually expressed in millisiemens per centimeter (mS / cm). For example, conductivity can be measured according to EPA (U.S. Environmental Protection Agency) Method No. 120.1.

[0562] Unless otherwise stated, the conductivity values ​​mentioned herein are normalized to 25°C.

[0563] The conductivity was measured using a conductivity meter (WTW Cond 3210 with quadrupole 325 electrodes).

[0564] Prior to use, the system was calibrated according to the instructions in the manual. To avoid local dilution, rinse the electrode thoroughly in the same medium as the one in which the measurement is to be made. Lower the electrode into the medium so that the area to be measured is completely immersed. Then stir the electrode to remove any air trapped on the electrode. Then keep the electrode still until a stable value can be obtained and recorded from the display.

[0565] Example 1.7: Determination of the total solid content of a solution

[0566] The total solids content of a solution can be determined according to NMKL 110 2nd edition, 2005 (Total solids (water) - Gravimetric determination in milk and milk products). NMKL is the "Nordisk Method for ” abbreviation.

[0567] The water content of a solution can be calculated as 100% minus the relative content of the total solids (% w / w).

[0568] Example 1.8: Determination of pH

[0569] All pH values ​​were measured using a pH glass electrode and normalized to 25 °C.

[0570] Carefully rinse and calibrate the pH glass electrode (with temperature compensation) before use. When the sample is in liquid form, measure the pH value directly in the liquid solution at 25°C. When the sample is a powder, dissolve 10 grams of powder in 90 mL of deionized water at room temperature with vigorous stirring. Then measure the pH value of the solution at 25°C.

[0571] Example 1.9: Determination of water content of powders

[0572] The moisture content of the food product is measured according to ISO 5537:2004 (Dried milk - Determination of moisture content (Reference method)).

[0573] Example 1.10: Determination of the amount of calcium, magnesium, sodium, potassium and phosphorus (ICP-MS method)

[0574] The total amounts of calcium, magnesium, sodium, potassium, and phosphorus were determined using the following steps: first microwave digestion was used to decompose the sample, and then an ICP instrument was used to determine the total amount of minerals.

[0575] instrument:

[0576] The microwave was from Anton Paar and the ICP was an Optima 2000DV from PerkinElmer Inc.

[0577] Material:

[0578] 1M HNO3

[0579] Yttrium in 2% HNO3

[0580] Suitable standard solutions of calcium, magnesium, sodium, potassium and phosphorus in 5% HNO3

[0581] Preprocessing :

[0582] Weigh out a certain amount of powder and transfer it to a microwave digestion tube. Add 5mL of 1M HNO3. Digest the sample in the microwave according to the microwave instructions. Place the digested tube in a fume hood and remove the lid to allow the volatile fumes to evaporate.

[0583] Measurement steps :

[0584] Transfer the pretreated sample to the DigiTUBE using a known amount of Milli-Q water. Add 2% yttrium solution in HNO3 to the digestion tube (approximately 0.25 mL per 50 mL of diluted sample) and dilute to a known volume using Milli-Q water. Analyze the sample on the ICP using the procedure described by the manufacturer.

[0585] Blind samples were prepared by diluting a mixture of 10 mL of 1 M HNO3 and 0.5 mL of a solution of yttrium in 2% HNO3 with Milli-Q water to a final volume of 100 mL.

[0586] Prepare at least 3 standards at the expected sample concentrations.

[0587] Example 1.11: Determination of furosine value:

[0588] The method for determining the furosine value is as described in Guerra-Hernandez et al., Maillard Reaction Evaluation by Furosine Determination During Infant Cereal Processing, Journal of Cereal Science 1999, 29: 171-176, and the total protein content is determined according to Example 1.1. The furosine value is expressed in mg creatinine / 100 g protein.

[0589] Example 1.12: Determination of the crystallinity of BLG in liquid

[0590] The following method was used to determine the crystallinity of BLG in liquids at pH 5-6.

[0591] a) Transfer 10 mL of the relevant liquid sample to a Maxi-Spin filter equipped with a 0.45 μm pore size CA membrane;

[0592] b) Immediately spin the filter at 1500 g for 5 minutes in a centrifuge maintained at 2°C;

[0593] c) 2 mL of cold Milli-Q water (2°C) was added to the retentate side of the spin filter, the filter was immediately spun at 1500 g for 5 minutes while keeping the centrifuge cooled at 2°C, the permeate was collected (Permeate A), the volume was measured, and the concentration of non-aggregated BLG was determined by HPLC using the method described in Example 1.2;

[0594] d) Add 4 mL of 2M NaCl to the retentate side of the filter, stir rapidly, and allow the mixture to stand at 25°C for 15 minutes;

[0595] e) immediately spinning the filter at 1500 g for 5 minutes and collecting the permeate (Permeate B);

[0596] f) Determine the total weight of non-aggregated BLG in permeate A and permeate B using the method described in Example 1.2, and convert the result into the total weight of non-aggregated BLG instead of weight percentage; the weight of non-aggregated BLG in permeate A is referred to as m 渗透物A The weight of non-aggregated BLG in permeate B is called m 渗透物B ;

[0597] g) The crystallinity of BLG in liquid was determined as follows:

[0598] Crystallinity = m 渗透物B / (m 渗透物A +m 渗透物B )*100%

[0599] Example 1.13: Determination of the crystallinity of BLG in dry powder

[0600] This method was used to determine the crystallinity of BLG in dry powder.

[0601] a) Mix 5.0 g of powder sample with 20.0 g of cold Milli-Q water (2°C) and let stand at 2°C for 5 minutes;

[0602] b) Transfer the liquid sample to a Maxi-Spin filter with a 0.45 μm CA membrane;

[0603] c) immediately spin the filter at 1500 g for 5 minutes in a centrifuge maintained at 2°C;

[0604] d) Add 2 mL of cold Milli-Q water (2°C) to the retentate side of the spin filter, then immediately spin the filter at 1500 g for 5 minutes, collect the permeate (Permeate A), measure the volume, and determine the concentration of non-aggregated BLG by HPLC using the method described in Example 1.2, and convert the result into the total weight of non-aggregated BLG instead of weight percentage. The weight of non-aggregated BLG in Permeate A is referred to as m 渗透物A ;

[0605] f) The crystallinity of BLG in the powder was then calculated using the following formula:

[0606]

[0607] Among them, m 总BLG is the total amount of non-aggregated BLG in the powder sample of step a).

[0608] If the total amount of non-aggregated BLG of a powder sample is unknown, it can be determined as follows: another 5 g powder sample (from the same powder source) is suspended in 20.0 g Milli-Q water, the pH value is adjusted to 7.0 by adding aqueous NaOH solution, the mixture is placed at 25°C for 1 hour under stirring, and finally the total amount of non-aggregated BLG of the powder sample is determined using Example 1.2.

[0609] Example 1.14: Determination of UF permeate conductivity

[0610] Transfer 15 mL of sample to an Amicon Ultra-15 centrifugal filter with a cutoff of 3 kDa (3000 NMWL) and centrifuge at 4000 g for 20-30 minutes, or until sufficient UF permeate accumulates at the bottom of the filter unit to measure conductivity. Measure conductivity immediately after centrifugation. Sample handling and centrifugation are performed at the temperature of the sample source.

[0611] Example 1.15: Determination of dried BLG crystals in powder

[0612] The presence of dried BLG crystals in a powder can be determined by the following method:

[0613] The powder sample to be analyzed was resuspended in deionized water at 4°C in a weight ratio of 2 parts water to 1 part powder, mixed gently, and then rehydrated at 4°C for 1 hour.

[0614] The rehydrated sample is examined microscopically to identify the presence of crystals, preferably using plane polarized light to detect birefringence.

[0615] The crystalline material is isolated and subjected to X-ray crystallographic analysis to verify the presence of the crystalline structure and preferably also that its lattice (space group and unit cell dimensions) corresponds to that of BLG crystals.

[0616] The chemical composition of the isolated crystalline material was analyzed to verify that the solid consisted mainly of non-aggregated BLG.

[0617] Example 1.16: Determination of total lactose content

[0618] The total amount of lactose is measured according to ISO 5765-2:2002 (IDF 79-2:2002) “Dried milk, dried ice-mixes and processed cheese – Determination of lactose content – ​​Part 2: Enzymatic method utilizing the galactose moiety of the lactose”.

[0619] Example 1.17: Determination of total carbohydrate content

[0620] Carbohydrate content was determined by using the Sigma Aldrich Total Carbohydrate Assay Kit (Cat. No. MAK104-1KT), in which carbohydrates are hydrolyzed and converted to furfural and hydroxyfurfural, then converted to a chromogen and monitored spectrophotometrically at 490 nm.

[0621] Example 1.18: Determination of total lipid content

[0622] Lipid content according to ISO 1211:2010 (Determination of fat content - -Gottlieb weight method, Determination of Fat Content- -Gottlieb Gravimetric Method).

[0623] Example 1.19: Determination of Brix

[0624] Brix was measured using a PAL-alpha digital handheld refractometer (Atago) calibrated with polished water (reverse osmosis filtered water, conductivity up to 0.05 mS / cm).

[0625] Transfer approximately 500 μL of sample to the prism surface of the instrument and begin taking measurements. Read and record the measurement.

[0626] The Brix of whey protein solution is proportional to the total solids (TS), and TS (% w / w) is approximately Brix*0.85.

[0627] Example 1.20: Determination of colony forming units

[0628] The number of colony forming units per gram of sample was determined according to ISO 4833-1:2013(E): Microbiology of food and animal feeding stuffs-horizontal method for the enumeration of microorganisms-Colony-count technique at 30°C.

[0629] Example 1.21: Determination of the total amount of BLG, ALA and CMP

[0630] This procedure is a liquid chromatography (HPLC) method for the quantitative analysis of proteins such as ALA, BLG and CMP as well as other proteins in a composition. Unlike the method of Example 1.2, this method also measures proteins present in aggregate, thus providing a measure of the total amount of protein species in the composition.

[0631] The separation method was size exclusion chromatography (SEC) using 6M guanidine hydrochloride buffer as the sample solvent and HPLC mobile phase.Mercaptoethanol was used as a reducing agent to reduce disulfide (SS) in proteins or protein aggregates to produce unfolded monomeric structures.

[0632] Sample preparation is easily accomplished by dissolving 10 mg protein equivalent in the mobile phase.

[0633] Two TSK-GEL G3000SWXL (7.7 mm × 30.0 cm) chromatographic columns (GPC chromatographic columns) and a guard column were placed in series to achieve adequate separation of the major proteins in the raw material.

[0634] The eluted analytes were detected and quantified by UV detection (280 nm).

[0635] Equipment / Materials :

[0636] 1. HPLC Pump 515 (Waters) with manual seal flush;

[0637] 2.HPLC pump control module II (Waters);

[0638] 3. Automatic sample injector 717 (Waters);

[0639] 4. Dual absorbance detector 2487 (Waters);

[0640] 5. Computer software capable of generating quantitative reports (Empower 3, Waters);

[0641] 6. Analytical columns: 2 TSK-GEL G3000SWXL (7.8×300mm, P / N: 08541);

[0642] Guard column: TSK-guard column SWxL (6.0×40 mm, P / N: 08543);

[0643] 7. Ultrasonic bath (Branson 5200);

[0644] 8.25 mm syringe filter with 0.2 μm cellulose acetate membrane. (514-0060, VWR).

[0645] program :

[0646] Mobile phase :

[0647] A. Stock Buffer

[0648] 1. Weigh 56.6g Na2HPO4, 3.5g NaH2PO4 and 2.9g EDTA into a 1000mL beaker. Dissolve in 800mL water;

[0649] 2. Measure the pH and, if necessary, adjust to 7.5 ± 0.1 with HCl (to lower the pH) or NaOH (to increase the pH);

[0650] 3. Transfer to a 1000mL volumetric flask and dilute to the mark with water.

[0651] B. 6M guanidine hydrochloride mobile phase

[0652] 1. Weigh 1146 g of guanidine hydrochloride and add it to a 2000 mL beaker, then add 200 mL of stock buffer (A);

[0653] 2. Dilute the solution to about 1600 mL with water while mixing with a magnetic stirring bar (50°C);

[0654] 3. Adjust pH to 7.5 ± 0.1 with NaOH;

[0655] 4. Transfer to a 2000mL volumetric flask and dilute to the mark with water;

[0656] 5. Filter using a solvent filtration device with a 0.22 μm membrane filter.

[0657] Calibration Standards

[0658] Calibration standards for each protein to be quantified were prepared as follows:

[0659] 1. Accurately weigh (to 0.01 mg) about 25 mg of protein reference standard into a 10 mL volumetric flask and dissolve in 10 mL of water. This is the protein stock standard solution (S1).

[0660] 2. Pipette 200 μL S1 into a 20 mL volumetric flask and dilute to volume with mobile phase. This is the low (concentration) working standard solution WS1.

[0661] 3. Pipette 500 μL S1 into a 10 mL volumetric flask and dilute to volume with mobile phase. This is standard solution WS2.

[0662] 4. Pipette 500 μL of S1 into a 5 mL volumetric flask and dilute to volume with mobile phase. This is standard solution WS3.

[0663] 5. Transfer 750 μL of S1 to a 5 mL volumetric flask and dilute to volume with mobile phase. This is standard solution WS4.

[0664] 6. Pipette 1.0 mL of S1 into a 5 mL volumetric flask and dilute to volume with mobile phase. This is the high (concentration) working standard solution WS5.

[0665] 7. Using a graduated disposable pipette, transfer 1.5 mL of WS1 to WS5 into individual vials, add 10 μL of 2-mercaptoethanol to each vial and cap the vial. Vortex the solution for 10 seconds and allow the standards to stand at ambient temperature for approximately 1 hour.

[0666] 8. Filter the standard solution using a 0.22 μm cellulose acetate syringe filter.

[0667] The purity of the protein was measured using the Kjeldahl method (N×6.38), and the area % of the standard solution WS5 was determined using HPLC.

[0668] Protein (mg) = "weight of protein standard" (mg) × P1 × P2;

[0669] P1 = P% (Kjeldahl method);

[0670] P2 = protein area % (HPLC).

[0671] Sample preparation

[0672] 1. Weigh 25 mg of the original protein sample into a 25 mL volumetric flask;

[0673] 2. Add about 20 mL of mobile phase and allow the sample to dissolve for about 30 minutes;

[0674] 3. Add mobile phase to the mark and add 167 μL 2-mercaptoethanol to 25 mL sample solution;

[0675] 4. Ultrasonic treatment for about 30 minutes, and then the sample is placed at ambient temperature for about 1.5 hours;

[0676] 5. The mixed solution was filtered using a 0.22 μL cellulose acetate syringe filter.

[0677] HPLC system / column

[0678] Equilibrate the column

[0679] 1. Connect a GPC guard column and two GPC analytical columns in series. The new column is usually filled with phosphate buffer.

[0680] 2. Allow water to flow through the new column gradually at a rate of 0.1 to 0.5 mL / min over 30 to 60 minutes. Continue flushing for about 1 hour.

[0681] 3. Gradually reduce the flow rate from 0.5 mL / min to 0.1 mL / min and replace the mobile phase in the storage container;

[0682] 4. Gradually increase the pump flow rate from 0.1 mL / min to 0.5 mL / min over 30 to 60 minutes to avoid pressure shock and maintain at 0.5 mL / min;

[0683] 5. Inject 10 samples to saturate the column and wait for the peak to elute. This will help condition the column. Do this without waiting for each injection to complete before the next injection.

[0684] 6. Equilibrate with mobile phase for at least 1 hour.

[0685] Calculation results

[0686] By comparing the peak area of ​​the corresponding standard protein with the peak area of ​​the sample, the quantitative determination of the content of the protein to be quantified (such as α-lactalbumin, β-lactoglobulin and casein macropeptide) is performed. The result is expressed as g specific protein / 100g original sample, or as the weight percentage of the specific protein relative to the weight of the original sample.

[0687] Example 2: Enrichment of α-lactalbumin in whey by removing β-lactoglobulin by crystallization

[0688] plan:

[0689] The lactose-deficient UF retentate from the sweet whey from the standard cheese production process was microfiltered using a 1.2 μm membrane and subsequently used as feedstock for the BLG crystallization process. The sweet whey feedstock was conditioned using an ultrafiltration unit with a Koch HFK-328 type membrane with a 46 mill interval, a feed pressure of 1.5-3.0 bar, a feed concentration of 21% TS (total solids) ± 5, and purified water (water filtered by reverse osmosis) as the diafiltration medium. The pH was then adjusted by adding HCl to obtain a pH of about 5.40. The diafiltration was continued until the conductivity of the retentate dropped below 0.03 mS / cm within 20 minutes. The retentate was then concentrated to about 30% TS (total protein of about 23.1% relative to the total weight of the concentrated retentate). A concentrated retentate was prepared at a temperature of 10-12°C. A sample of the concentrated retentate was centrifuged at 3000 g for 5 minutes, but no visible precipitate was formed. The supernatant was subjected to HPLC analysis. The composition of the raw materials is shown in Table 1.

[0690] It should be noted that in this example, the concentrations of all specific proteins (eg BLG and ALA) are related to the concentration of non-aggregated proteins, measured according to Example 1.2.

[0691] The concentrated retentate was seeded with 0.5 g / L of pure BLG crystalline material obtained by spontaneous BLG crystallization (as described in Example 3 of PCT application PCT / EP2017 / 084553). The seed material was prepared by washing the BLG crystal slurry 5 times in MilliQ water and collecting the BLG crystals after each wash. After washing, the BLG crystals were freeze-dried, ground with a pestle and mortar, and then passed through a 200 μm sieve. Therefore, the particle size of the seed crystals was less than 200 μm.

[0692] The concentrated retentate was transferred to a 300 L crystallizer where it was cooled to about 2 ° C and kept at this temperature with slow stirring overnight. The next morning, a sample of the cooled concentrated retentate was transferred to a test tube and examined visually and by microscopy. Rapidly precipitated crystals had apparently formed overnight. A laboratory sample of a mixture comprising crystals and mother liquor was further cooled to 0 ° C in an ice-water bath. Mother liquor and crystals were separated by centrifugation at 3000 g for 5 minutes, and samples of the supernatant and precipitate were taken for HPLC analysis. The crystals were washed once in cold refined water and then centrifuged again before freeze drying.

[0693] Table 1: Concentrations of selected components of feedstock (normalized to 95% w / w total solids)

[0694]

[0695] Protein analysis:

[0696] Protein quantification was performed using TSK-HPLC with standards and total protein concentration was measured using the Kjeldahl method with a factor of 6.38.

[0697] Quantification of BLG relative yield by HPLC:

[0698] All samples were diluted to the same extent by adding purified water and filtered through a 0.22 μm filter. The same volume of each sample was injected into a 5μm C4 LC column 250×4.6 mm, EA HPLC system. Detection at 214 nm.

[0699] The samples were run under the following conditions:

[0700] Buffer A: MilliQ water, 0.1% w / w TFA

[0701] Buffer B: HPLC grade acetonitrile, 0.085% w / w TFA

[0702] Column temperature: 40°C

[0703] Flow rate: 1mL / min

[0704] Gradient: 0-30 min 82-55% A and 18-45% B; 30-32 min 55-10% A and 45-90% B; 32.5-37.5 min 10% A and 90% B; 38-48 min 10-82% A and 90-18% B.

[0705] Data processing:

[0706] Since all samples were processed in the same way, we can directly compare the areas of the BLG peak to obtain relative yields. Since the crystals contained only BLG and all samples were processed in the same way, the α-lactalbumin (ALA) concentration and ALA area should be the same in all samples, so the ALA area before and after crystallization was used as a correction factor (cf) when calculating relative yields.

[0707]

[0708] The relative yield was calculated by the following formula:

[0709]

[0710] Enrichment of other proteins in the mother liquor:

[0711] Based on the conservation of mass and the known relative removal of BLG, assuming that no other proteins are removed except BLG, the protein composition of the raw material is measured and the protein composition of the mother liquor is calculated. Thus:

[0712]

[0713] m 蛋白质ML =m 蛋白质原料 -m 晶体形式的BLG

[0714] m ALA原料 =m ALA ML

[0715]

[0716]

[0717]

[0718] result:

[0719] Figure 1 Overlay chromatograms are shown before and after crystallization of BLG from sweet whey. The "before crystallization" sample is represented by the solid black line and the "after crystallization" sample is represented by the dashed line. Clearly, the concentration of BLG has been greatly reduced, and using the yield calculation as described previously, it was found that 64.5% of BLG was removed. Measured % ALA ML The ALA yield was close to 100% because almost no ALA was removed by using BLG crystals. Figure 2 A photograph of a BLG crystal is shown, Figure 3 A chromatogram of the dissolved crystals is shown, indicating that hardly any non-BLG protein was removed by the BLG crystals.

[0720] Table 2 shows the calculated protein composition of the mother liquor.

[0721] Table 2: Calculated protein composition of the mother liquor

[0722]

[0723] in conclusion:

[0724] Unexpectedly, this example demonstrates that an ALA-enriched whey protein composition can be prepared by selectively crystallizing BLG in a crude whey protein concentrate containing more than 48% non-BLG protein relative to the total amount of protein, followed by removal of the BLG crystals. The yield of ALA is close to 100%. This discovery provides a new method for industrial milk protein separation that removes BLG from ALA and other protein components in a gentle manner, better avoiding prolonged exposure to high temperatures and problematic chemicals.

[0725] Example 3: Enrichment of ALA and other proteins from whey protein concentrate from sweet whey by removing BLG through crystallization Whey protein types

[0726] plan:

[0727] The lactose-deficient UF retentate from sweet whey from a standard cheese production process was filtered through a 1.2 μm filter and then fat reduced using a Synder FR membrane. The permeate was then prepared for crystallization as described in Example 2, except that no seed was added. The composition of the feedstock is shown in Table 3. The data was then processed as described in Example 2.

[0728] Table 3: Concentrations of selected components of feedstock (normalized to 95% w / w total solids)

[0729]

[0730] It should be noted that in this example, the concentrations of all specific proteins (eg BLG and ALA) are related to the concentration of non-aggregated proteins, measured according to Example 1.2.

[0731] result:

[0732] exist Figure 4 The protein composition of the feed and mother liquor is shown. Clearly, most of the BLG has been removed and the yield was calculated as described in Example 2, giving a BLG yield of 82%. % ALA obtained ML The protein composition of the mother liquor is shown in Table 4.

[0733] Table 4: Calculated protein composition of the mother liquor

[0734]

[0735] Example 4: Enrichment of ALA and other proteins from whey protein concentrate from acid whey by removing BLG through crystallization Whey protein types

[0736] plan:

[0737] Acid whey was used as raw material and processed as described in Example 2. The raw material was crystallized as described in Example 2 and the resulting product was characterized and analyzed as described in Example 2. Table 5 shows the concentrations of selected components of the raw material.

[0738] Table 5: Concentrations of selected components of feedstock (normalized to 95% w / w total solids)

[0739]

[0740] exist Figure 5The protein composition of the raw material and the mother liquor is shown. Obviously, most of the BLG has been removed. The BLG yield of the crystal separation was measured to be 70.3%. If the concentration of total protein was higher before crystallization, the yield would be higher. In this example, ALA was enriched by 81%, resulting in an ALA percentage of 43.4. The protein composition of the remaining whey protein solution (mother liquor) is shown in Table 6.

[0741] Table 6: Calculated protein composition of the mother liquor

[0742]

[0743] It should be noted that in this example, the concentrations of all specific proteins (eg, BLG and ALA) are relative to the concentration of non-aggregated proteins.

[0744] In addition to the increased level of ALA, the recovered mother liquor also contains whey fat rich in phospholipids and immunoglobulins of the original whey protein raw material. These are considered to be components with nutritional value in infant nutrition, for example for the development of cognitive functions and immune system of infants. Therefore, the whey protein composition prepared from the recovered mother liquor is particularly suitable as a component of humanized infant nutrition products.

[0745] Example 5: Enrichment of ALA and other proteins from whey protein concentrate derived from serum proteins by removal of BLG by crystallization Other whey protein types

[0746] Skim milk was used as the feedstock and casein was removed by passing through a Synder FR membrane. The permeate was then prepared for crystallization as described in Example 2 and the data were processed as described in Example 2.

[0747] See Table 7.

[0748] Table 7: Concentrations of selected components of feedstock (normalized to 95% w / w total solids)

[0749]

[0750] It should be noted that in this example, the concentrations of all specific proteins (eg, BLG and ALA) are relative to the concentration of non-aggregated proteins.

[0751] Likewise, it was observed that most of the BLG had been removed. The yield of BLG was measured to be 70.0%. If the total solids of the concentrated retentate were higher before and / or during crystallization, the yield would be higher. In this example, ALA was enriched by 88%, resulting in an ALA content of 44.1% w / w in the mother liquor relative to the total protein. Table 8 shows the calculated protein composition of the mother liquor.

[0752] Table 8: Calculated protein composition of the mother liquor

[0753]

[0754] in conclusion:

[0755] Using the method of the present invention it is possible to significantly enrich the ALA portion of the protein from all feedstocks tested, thereby providing an ALA-enriched whey protein product which can be used as an ALA ingredient as such or can be further enriched.

[0756] Example 6: UF-DCF assisted crystallization

[0757] Serum was obtained by microfiltration of skim milk (microfiltration using a Synder FR membrane) and used as feedstock for the process described in Example 2 except that the pH during diafiltration was 5.92 instead of 5.40 and the final total solids was 20% w / w.

[0758] After conditioning the feedstock (see Table 9 for feedstock composition), it was transferred to a 300 L crystallizer, the pH was first adjusted to pH 5.80, and the temperature was maintained at about 10-12° C. After pH adjustment, seed material was added, which was produced in the same manner as described in Example 2, but derived from a non-spontaneous crystallization production. The feedstock was seeded at a concentration of 0.5 g seed material / L feedstock. After seeding, the temperature of the cooling hood was set to 5° C., the pH was slowly adjusted to 5.50, crystallization was allowed to proceed for about one hour, and then a DCF (dynamic cross flow filtration) was connected to the crystallizer, as shown. Figure 6 The retentate from the DCF was returned to the crystallization tank, while the permeate was used as feed to an ultrafiltration unit equipped with a Koch HFK-328 type membrane with a 46 mill spacing. The DCF unit was equipped with a Kerafol ceramic membrane with a pore size of 500 nm. The transmembrane pressure (TMP) was set to 0.4 bar and the rotation speed of the membrane was 32 Hz.

[0759] The retentate from DCF is returned to the crystallizer, while the permeate is used as a feedstock for a UF (ultrafiltration) device equipped with a Koch HFK-328 type membrane with a 46 mill interval. In the ultrafiltration device, the temperature is raised to but not exceeding 12°C. The amount of diafiltration water added is adjusted so that the retentate coming out of the ultrafiltration device and returning to the crystallizer is about 21% TS, while removing minerals from the mother liquor. Diafiltration of the mother liquor continues until the conductivity difference between the permeate and the diafiltration water is less than 50 mS / cm. At this point, the amount of diafiltration water is adjusted so that the retentate is about 30% TS. The total amount of solids in the mother liquor decreases as BLG is removed as crystals. This continuous removal of excess water and minerals can increase the yield of BLG because the concentration of non-BLG proteins during the BLG crystallization process seems to have limited effect on the solubility of BLG. Table 10 lists the estimated composition of the mother liquor from DCF (DCF permeate). The initial 300L feedstock was reduced to about 100L of mother liquor. Based on mass conservation, the relative yield of BLG was estimated to be 94% relative to the ALA concentration in the starting material, and the ALA concentration relative to total protein was estimated to increase by 267%.

[0760] Table 9: Concentrations of selected components of raw materials (normalized to 95% w / w TS)

[0761]

[0762] It should be noted that in this example, the concentrations of all specific proteins (eg BLG and ALA) are related to the concentration of non-aggregated proteins, measured according to Example 1.2.

[0763] Table 10: Estimated protein composition of mother liquor

[0764]

[0765] in conclusion:

[0766] By continuously removing excess minerals and water from the matrix in which BLG crystallization occurs, the enrichment of ALA can be significantly improved, and this process can be accomplished at low temperatures.

[0767] Example 7: Solving the problem of mother liquor treatment by acidification

[0768] The inventors have previously observed that direct concentration and spray drying of mother liquors causes scaling problems and membrane clogging, requiring extensive heat treatment to bring the microbial load to acceptable levels. Due to the relatively harsh heat treatment required, the resulting dry powder will have poor protein solubility.

[0769] The pH of the mother liquor was adjusted from 5.5 to 3.2.

[0770] 730 kg of mother liquor were recovered from a crystallization similar to that outlined in Example 3 and stored overnight at 5°C. The recovered mother liquor contained approximately 4.6% w / w protein and the chemical composition is shown in Table 11. The pH of the mother liquor was adjusted to 3.2 by slowly adding dilute phosphoric acid. This step was performed to dissolve the remaining BLG crystals. The bacterial analysis of the mother liquor at the initial pH and after pH adjustment was analyzed according to Example 1.20 and the results are shown in Table 12.

[0771] Table 11: Chemical composition of selected components of mother liquor (normalized to 95% total solids)

[0772] Components %w / w protein 85 Ca 0.59 Cl 0.75 Fat 0.75 K 0.41 Mg 0.11 Na 0.10 P 0.30

[0773] Notably, a change in turbidity from 86.8 NTU (in mother liquor) to 23.7 NTU (in pH adjusted mother liquor) was observed.

[0774] Removal of bacteria from the mother liquor during the microfiltration step

[0775] To remove bacteria, the mother liquor at a pH of about 3.2 was passed through a 0.8 mm ceramic membrane (Pall Membralox GP). The microfiltration step was carried out at an operating temperature of about 10° C., with a transmembrane pressure of 3.2 bar and a permeate flow rate fixed at 60 L / h / membrane. The permeate was collected for further processing. At the end of the MF step, the turbidity of the collected MF permeate was about 15.2 NTU. The permeate was analyzed according to Example 1.20.

[0776] Treatment of the mother liquor during the ultrafiltration step

[0777] The permeate collected from the microfiltration step was filtered using a 48 mill spacing spiral wound GR82PE UF membrane (molecular weight cut-off 5 kDa). In the ultrafiltration step, the mother liquor was concentrated to about 16 Brix (about 12% w / w protein). To avoid pH changes during the filtration step, additional phosphoric acid was added.

[0778] In this step, a concentration factor of 3 was achieved (about 185 kg of concentrated MF permeate was collected). Higher concentration factors can be achieved if filtration is continued. In this example, the raw material had a Brix and pH of about 16.5 and 3.3, respectively, and the raw material was collected and sent to a spray dryer. The mother liquor at acidic pH after the ultrafiltration step was analyzed according to Example 1.20.

[0779] Drying of the pH adjusted concentrated mother liquor

[0780] A portion of the pH adjusted concentrated mother liquor was dried using a spray dryer with an inlet temperature of 185° C. and an outlet temperature of about 85° C. The resulting powder (about 15 kg) had a water content of about 4.0% w / w. The microbial content was analyzed according to Example 1.20.

[0781] result:

[0782] As can be seen in Table 12, the addition of acid to adjust the pH of the mother liquor from about 5.5 to 3.2 resulted in a reduction in the total plate count by about 10-fold. In addition, the microfiltration step successfully removed bacteria as the total plate count of the permeate was reduced to <1000 CFU / g. After spray drying, the final mother liquor powder at pH 3.2 had a total plate count of 10 CFU / g.

[0783] Table 12: Microbial concentration after each treatment step (CFU / g)

[0784]

[0785] In addition, the stock solution after adjusting the pH to 3.2 was stored at 5°C for three days. The total plate count decreased from 460,000 CFU / g to 350,000 CFU / g. The decrease in the total plate count of the samples before and after storage indicates that keeping the stock solution at an acidic pH of 3.2 can also inhibit bacterial growth.

[0786] in conclusion:

[0787] Acidification of the mother liquor powder to produce a pH of 3.2 resulted in a significant reduction in bacterial load. In addition, the turbidity of the mother liquor was reduced from about 87 NTU to 24 NTU, which is believed to be a result of dissolution of BLG crystals and / or a reduction in microbial load in the mother liquor.

[0788] Furthermore, microfiltration of the mother liquor resulted in successful removal of bacteria. Furthermore, the final powder, using a pH of about 3.2, had a transparent appearance with a turbidity below 50 NTU. Thus, the acidic powder derived from the conditioned mother liquor can be used in beverage and instant beverage applications, such as for pediatric nutrition.

[0789] Example 8: Solving the problem of mother liquor treatment by increasing pH

[0790] 400 mL of mother liquor at pH about 5.5 was mixed with diluted KOH to obtain a pH of about 7. The pH adjusted mother liquor was subjected to a filtration step using a Synder HFK328 membrane at a transmembrane pressure of 4 bar and a temperature of about 10°C until a solids content of 6 Brix was reached.

[0791] result:

[0792] After the ultrafiltration step, the mother liquor contained 89% protein relative to the total solids. Due to the pH adjustment, no scaling problems or membrane clogging problems were encountered. If the pH-adjusted concentrated mother liquor is concentrated to a higher total solids, it appears to be suitable for drying or can be used directly without further modification as an ingredient in, for example, pediatric nutritional foods or instant beverages.

[0793] Example 9: Further enrichment of ALA from the mother liquor

[0794] This example describes the further enrichment of the mother liquor for ALA.

[0795] 100 L of mother liquor with a protein content of about 13.7% w / w was obtained according to Example 5 and mixed with hydrochloric acid (8% w / v) and mixed rapidly to reach a final pH of 4.3. The pH-adjusted mother liquor was then concentrated by ultrafiltration in a four-stage series ultrafiltration device using a 5 kDa UF membrane to a protein content of about 22% w / w. The pH-adjusted concentrated mother liquor was then passed through a tubular heat exchanger, in which the temperature was slowly raised to 64°C ± 1°C, and then passed through a tube maintained at the same temperature, the length of which was equal to the residence time of 6 minutes. The solution was then cooled to 50°C in a second tubular heat exchanger and collected in an insulated barrel equipped with a stirring paddle rotating at a speed of 20 rpm. After an average residence time of 10 minutes in the barrel, the solution was pumped through a continuous automatic slag clarifier at a rate of 200 L / hour. After flushing the clarifier with water, the precipitated protein fraction was discharged regularly. The precipitated protein fraction was suspended in purified water and dissolved by adding an aqueous NaOH solution (10% w / v) to adjust the pH to 6.7.

[0796] The dissolved protein fraction was concentrated by ultrafiltration using a 5 kDa membrane to a total solids content of about 25% w / w and spray dried. The ALA-enriched powder is expected to contain more than 60% w / w ALA relative to the total protein content and a total protein content of at least 85% relative to the total solids of the powder. The water content is at most 5% w / w.

[0797] Example 10: Infant formula containing an ALA-enriched whey protein composition

[0798] Two infant formulas, A and B, were produced from the ALA-enriched whey protein powder of Example 4 or 9 by mixing:

[0799] - 6.8 kg of ALA-enriched whey protein powder from Example 4 (for infant formula A) or Example 9 (for infant formula B);

[0800] -20.5kg food grade lactose;

[0801] -152.7 kg water;

[0802] - 70 kg ultrafiltered concentrated skim milk (9.0% w / w protein, 4.2% w / w lactose, 0.05% w / w fat, 0.7% w / w ash, 14.7% w / w total solids);

[0803] - 374 kg of desalinated ultrafiltration permeate of skim milk;

[0804] - 33.2 kg vegetable fat mixture;

[0805] - 15.1 kg of GOS syrup with a total solid content of 71%;

[0806] -Required micronutrients, including vitamins, nucleotides and polyunsaturated fatty acids (PUFAs).

[0807] The blend was homogenized, pasteurized, evaporated and spray dried to give 118 kg of final infant formula with a whey protein / casein ratio of about 62 / 38 and an energy content of about 2000 kJ / 100 g powder.

[0808] Both infant formulas mimic human breast milk better than standard whey protein-based infant formulas. Both infant formulas, especially infant formula B, contain higher levels of ALA than standard whey protein-based infant formulas. Infant formula A also contains phospholipid-rich whey fat and immunoglobulins from raw whey protein ingredients, which are considered nutritionally valuable ingredients in infant nutrition foods, such as for the development of cognitive functions and immune systems in infants.

Claims

1. A method for preparing an edible whey protein composition rich in α-lactalbumin, in, The method comprises the following steps: a) providing a whey protein solution, wherein the whey protein solution comprises non-aggregated β-lactoglobulin (BLG) and α-lactalbumin (ALA), wherein the whey protein solution is supersaturated with BLG and has a pH of 5 to 6; b) crystallization of non-aggregated BLG in a supersaturated whey protein solution in a salting mode; and c) separating the BLG crystals from the remaining mother liquor and recovering at least some of the mother liquor; d) providing a first composition, said first composition being derived from the recovered mother liquor; f) Drying: - said first composition or its protein concentrate obtained from step d).

2. The method according to claim 1, in, The whey protein solution further comprises other whey proteins.

3. The method according to claim 1, in, The method further comprises step e): after step d) and before step f) : The pH of the first composition is adjusted to: i) pH 2.5 to 4.9; or ii) pH 6.1-8.5; as well as In step f), the pH adjusted first composition or its protein concentrate obtained from step e) is dried.

4. The method according to claim 2, in, The method further comprises step e): after step d) and before step f) : The pH of the first composition is adjusted to: i) pH 2.5 to 4.9; or ii) pH 6.1-8.5; as well as In step f), the pH adjusted first composition or its protein concentrate obtained from step e) is dried.

5. The method according to claim 1 or 2, in, The method also includes physically reducing the microorganisms.

6. The method according to claim 3 or 4, in, The method also includes physically reducing the microorganisms.

7. The method according to claim 6, in, The physical reduction of microorganisms is carried out after the pH adjustment in step e) and before the drying in step f).

8. The method according to any one of claims 1 to 4 and claim 7, in, The whey protein solution of step a) comprises at most 90% w / w BLG relative to the total amount of protein.

9. The method according to claim 5, in, The whey protein solution of step a) comprises at most 90% w / w BLG relative to the total amount of protein.

10. The method according to any one of claims 1 to 4 and claim 7, in, The whey protein solution comprises whey protein concentrate, whey protein concentrate, whey protein isolate and / or whey protein isolate.

11. The method according to claim 5, in, The whey protein solution comprises whey protein concentrate, whey protein concentrate, whey protein isolate and / or whey protein isolate.

12. The method according to any one of claims 1 to 4 and claim 7, in, The ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.

3.

13. The method according to claim 5, in, The ratio between the electrical conductivity of the whey protein solution and the total amount of protein is at most 0.

3.

14. The method according to any one of claims 1 to 4 and claim 7, in, The UF permeate conductivity of the whey protein solution is at most 7 mS / cm.

15. The method according to claim 5, in, The UF permeate conductivity of the whey protein solution is at most 7 mS / cm.

16. The method according to any one of claims 1 to 4 and claim 7, in, The supersaturated whey protein solution is prepared by subjecting the whey protein raw material to one or more adjustments, the adjustments comprising: - pH adjustment; - Reduce electrical conductivity; - Reduce the temperature; - Increase protein concentration; and - Addition of agents that reduce water activity.

17. The method according to claim 5, in, The supersaturated whey protein solution is prepared by subjecting the whey protein raw material to one or more adjustments, the adjustments comprising: - pH adjustment; - Reduce electrical conductivity; - Reduce the temperature; - Increase protein concentration; and - Addition of agents that reduce water activity.

18. The method according to any one of claims 1 to 4 and claim 7, in, Step c) comprises isolating the BLG crystals to a solids content of at least 30% w / w.

19. The method according to claim 5, in, Step c) comprises isolating the BLG crystals to a solids content of at least 30% w / w.

20. The method according to any one of claims 1 to 4 and claim 7, in, Step c) comprises isolating the BLG crystals to a solids content of at least 40% w / w.

21. The method according to claim 5, in, Step c) comprises isolating the BLG crystals to a solids content of at least 40% w / w.

22. The method according to any one of claims 1 to 4 and claim 7, in, Step c) comprises isolating the BLG crystals to a solids content of at least 50% w / w.

23. The method according to claim 5, in, Step c) comprises isolating the BLG crystals to a solids content of at least 50% w / w.

24. The method according to any one of claims 1 to 4 and claim 7, in, The first composition comprises or even consists of the recovered mother liquor.

25. The method according to claim 5, in, The first composition comprises or even consists of the recovered mother liquor.

26. The method according to any one of claims 1 to 4 and claim 7, in, The first composition comprises or even consists of a protein concentrate of the recovered mother liquor.

27. The method according to claim 5, in, The first composition comprises or even consists of a protein concentrate of the recovered mother liquor.

28. The method according to any one of claims 1 to 4 and claim 7, in, Providing the first composition includes further enriching for ALA.

29. The method according to claim 5, in, Providing the first composition includes further enriching for ALA.

30. The method according to claim 28, in, The further enrichment of ALA is performed to obtain the first composition, wherein the weight percentage of ALA relative to the total amount of protein in the first composition is at least 5% higher than that in the recovered mother liquor.

31. The method according to claim 29, in, The further enrichment of ALA is performed to obtain the first composition, wherein the weight percentage of ALA relative to the total amount of protein in the first composition is at least 5% higher than that in the recovered mother liquor.

32. The method according to any one of claims 3 to 4 and claim 7, in, The pH of the first composition is adjusted to 2.5-4.

9.

33. The method according to claim 6, in, The pH of the first composition is adjusted to 2.5-4.

9.

34. The method according to any one of claims 3 to 4 and claim 7, in, The pH of the first composition is adjusted to 2.8-4.

5.

35. The method according to claim 6, in, The pH of the first composition is adjusted to 2.8-4.

5.

36. The method according to any one of claims 3 to 4 and claim 7, in, The pH of the first composition is adjusted to 2.8-3.

2.

37. The method according to claim 6, in, The pH of the first composition is adjusted to 2.8-3.

2.

38. The method according to any one of claims 3 to 4 and claim 7, in, The pH of the first composition is adjusted to 6.1-8.

5.

39. The method according to claim 6, in, The pH of the first composition is adjusted to 6.1-8.

5.

40. The method according to any one of claims 3 to 4 and claim 7, in, The pH of the first composition is adjusted to 6.3-8.

0.

41. The method according to claim 6, in, The pH of the first composition is adjusted to 6.3-8.

0.

42. The method according to any one of claims 3 to 4 and claim 7, in, The pH of the first composition is adjusted to 6.5-7.

5.

43. The method according to claim 6, in, The pH of the first composition is adjusted to 6.5-7.

5.

44. The method according to claim 5, in, The physical reduction of microorganisms comprises one or more of the following steps: - heat treatment; - UV radiation treatment; - Pulsed light treatment; - Microfiltration; - High pressure treatment; and - Sonication.

45. The method according to claim 7, in, The physical reduction of microorganisms comprises one or more of the following steps: - heat treatment; - UV radiation treatment; - Pulsed light treatment; - Microfiltration; - High pressure treatment; and - Sonication.

46. ​​The method according to claim 5, in, The physical reduction of microorganisms includes at least pasteurization.

47. The method according to claim 7, in, The physical reduction of microorganisms includes at least pasteurization.

48. The method according to any one of claims 1 to 4 and claim 7, in, The first composition of step d) has at least the same weight percentage of ALA as the recovered mother liquor, relative to the total amount of protein in the first composition.

49. The method according to claim 5, in, The first composition of step d) has at least the same weight percentage of ALA as the recovered mother liquor, relative to the total amount of protein in the first composition.

50. An edible ALA-enriched whey protein composition, in, The composition can be obtained by the method according to any one of claims 1 to 49, and the composition comprises: - 24-80% w / w ALA relative to total protein; - Immunoglobulins with a content of 3-14% w / w relative to the total protein.

51. An edible ALA-enriched whey protein composition according to claim 50, in, The composition further comprises phospholipids in an amount of 1-6% w / w relative to the total amount of protein.

52. An edible ALA-enriched whey protein composition according to claim 50 or 51, in, The composition comprises 24-70% w / w ALA relative to the total amount of protein.

53. An edible ALA-enriched whey protein composition according to claim 51, in, The composition comprises phospholipids in an amount of 2-5% w / w relative to the total amount of protein.

54. An edible ALA-enriched whey protein composition according to claim 50 or 51, in, The furosine value of the composition is at most 50 mg / 100 g protein.

55. A method of producing a food product, in, The method comprises the following steps: a) providing a whey protein solution, wherein the whey protein solution comprises non-aggregated β-lactoglobulin (BLG) and α-lactalbumin (ALA), wherein the whey protein solution is supersaturated with BLG and has a pH of 5 to 6; b) crystallization of non-aggregated BLG in a supersaturated whey protein solution in a salting mode; and c) separating the BLG crystals from the remaining mother liquor and recovering at least some of the mother liquor; d) providing a first composition, said first composition being derived from the recovered mother liquor; g) mixing the following with one or more ingredients and converting the resulting mixture into a food product: g1) said first composition or its protein concentrate obtained from step d).

56. The method according to claim 55, in, The whey protein solution further comprises other whey proteins.

57. The method according to claim 55 or 56, in, The method comprises step e): after step d) and before step g) : The pH of the first composition is adjusted to: i) pH 2.5 to 4.9; or ii) pH 6.1-8.5; as well as In step g), the following components are mixed with one or more ingredients and the obtained mixture is converted into a food product: g1) the first composition or its protein concentrate obtained in step d); and / or g2) The pH-adjusted first composition or its protein concentrate obtained from step e).

58. The method according to claim 57, in, The method comprises step f): after step e) and before step g) : drying the first composition or its protein concentrate obtained from step d); or drying the pH-adjusted first composition or its protein concentrate obtained from step e); and In step g), the following components are mixed with one or more ingredients and the obtained mixture is converted into a food product: g1) the first composition or its protein concentrate obtained in step d); g2) the pH-adjusted first composition or its protein concentrate obtained from step e); and / or g3) The dried composition obtained from step f).